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Abstract: 
In this study, two separate methods were developed and validated for two different 
products to track three leachables; cyclohexanone, propylene glycol monoethyl ether 
acetate (PGMEEA), and propylene glycol monomethyl ether acetate (PGMMEA). 
These leachables were recently discovered to be leaching from an ink that is applied 
during labelling to a plastic vial containing the sample, a process known as 
tampoprinting.  
Due to the volatile nature of these leachables the best technique of tracking them is 
by gas chromatography (GC). This analytical separation technique utilises a system 
that vaporises liquid samples containing organic compounds of interest. The sample 
travels through a column where the sample components are separated and then 
detected producing a quantitative measurement of each component.  
In chapter 2, a direct injection gas chromatography method was developed for 
Product Z to track the three leachables of interest. The method was then fully 
validated in accordance with the current United States Pharmacopeia (USP) Category 
II for leachables and in line with all requirements under International Conference on 
Harmonisation (ICH) Q2 (R1). 
In chapter 3, direct injection gas chromatography could not be utilised for Product X 
due to the different nature of its sample matrix to Product Z. Instead, a method to 
track the Tampoprint leachables was developed using headspace GC, a slightly 
different technique whereby volatile compounds from the sample are evaporated 
from the liquid before being injected onto the GC column. This prevents much of the 
sample matrix from going onto the column and thus produces much cleaner 
chromatography. This method was then also fully validated in accordance with USP 
requirements and ICH guidelines. 
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Glossary of Terms: 
Accuracy  
The accuracy of an analytical procedure expresses the closeness of agreement 
between the value which is accepted either as a conventional true value or an 
accepted reference value and the value found. 
 
Analytical Procedure 
The analytical procedure refers to the way of performing the analysis. It should 
describe in detail the steps necessary to perform each analytical test. This may 
include but is not limited to: the sample, the reference standard and the reagents 
preparations, use of the apparatus, generation of the calibration curve, use of the 
formulae for the calculation.  
 
Asymmetry / Tailing Factor (Tf) 
A measure of how close a chromatographic peak is to a symmetrical shape. As a 
peak slopes the tailing factor increases. 
Tf = ac / 2ab 
where ac is the peak width at 5% of the peak height, and ab is the front half-width 
measured from the leading edge to a perpendicular dropped from the peak apex. 
An ideal chromatography peak is a sharp symmetrical shape, a Gaussian peak, on a 
flat baseline. A peak can deviate from this ideal in several different ways. It can 
become asymmetrical, flatten and become broader, or the baseline can rise. One of 
the common shifts away from a Gaussian peak is when the back half of the peak falls 
away. If the peak were split into two, vertically, the latter half would be wider than 
the first half of the peak. This effect is most clearly seen close to the baseline and is 
known as peak tailing. In Gas Chromatography (GC) tailing can be a result of a 
poorly installed column, inlet contamination, column blockages, solvent polarity 
mismatch or a low split ratio. 
Fronting peaks are the opposite of tailing peaks in that the first half of the peak 
would be wider than the latter half. They usually occur when the sample capacity of 
the analytical column is exceeded. This overloading effect usually results from 
injecting too much sample. Fronting peaks may also be a result of poor column 
installation or co-elution. 
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Capacity Factor (k) 
Expression that measures the degree of retention of an analyte relative to an 
unretained peak, where tR is the retention time for the sample peak and t0 is the 
retention time for an unretained peak. A measurement of capacity will help 
determine whether retention shifts are due to the column (capacity factor is changing 
with retention time changes) or the system (capacity factor remains constant with 
retention time changes).  Thus the higher the capacity factor, the longer the retention 
time. 
K = tR - t0 
          t0 
 
Conventional Ultra Violet-Visible (UV-Vis) Detector 
A detector analyses individual wavelengths as they are scanned across the full 
spectrum or spectrum of interest for a particular sample. 
 
Detection Limit 
The detection limit of an individual analytical procedure is the lowest amount of 
analyte in a sample which can be detected but not necessarily quantitated as an exact 
value. Typically the detection limit will be equal to 3 times the standard deviation of 
the blank. For validation purposes the detection limit may often be set at one third of 
the quantitation limit as concentration levels can become so small they are regarded 
as zero. 
 
Distribution Coefficient (Log D) 
The ratio of the sum of the concentrations of all forms of the compound (ionised plus 
un-ionised) in each of the two phases. It is a measure of how hydrophobic or 
hydrophilic a given compound is taking into account the ionised state of a 
compound. Thus, Log D is always expressed as a function of pH.  
Log D = Log ([Analyte]octanol / ([Analyte ionised]water + [Analyte neutral]water )) 
 
Extractable  
Chemicals that migrate from the product-contact component into a solvent at 
accelerated conditions (such as heat, time, pH, ionic strength, organic solvent 
content). 
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Flame Ionisation Detector (FID) 
Flame ionisation detectors (FID) are the most generally applicable and most widely 
used GC detectors.  In an FID, the sample is directed at an air-hydrogen flame after 
exiting the column.  At the high temperature of the air-hydrogen flame, the sample 
undergoes pyrolysis, or chemical decomposition through intense heating.  Pyrolised 
hydrocarbons release ions and electrons that carry current.  A high-impedance 
picoammeter measures this current to monitor the sample's elution. 
It is advantageous to use FID as the detector is unaffected by flow rate, non-
combustible gases and water.  These properties allow FID high sensitivity and low 
noise.  The unit is both reliable and relatively easy to use.  
 
Flow Rate 
The speed at which the carrier gas travels through the column. The higher the flow 
rate the shorter the retention time.  
 
GC Column 
A glass or metal tube through which the sample can travel as a gas. The choice of 
column depends on the sample and the active measured. The main chemical attribute 
regarded when choosing a column is the polarity of the mixture. The polarity of the 
sample must closely match the polarity of the column stationary phase to increase 
resolution and separation while reducing run time. The separation and run time also 
depends on the film thickness (of the stationary phase), the column diameter and the 
column length. 
 
Headspace 
Using the known temperature of the sample, the bottle volume, the concentrations of 
gas in the headspace (as determined by GC), and Henry’s law constant, the 
concentration of the original water sample is calculated. Total gas concentration (TC) 
in the original water sample is calculated by determining the concentration of 
headspace and converting this to the partial pressure and then solving for the aqueous 
concentration which partitioned in the gas phase (CAH) and the concentration 
remaining in the aqueous phase (CA). The total concentration of gas in original 
sample (TC) is the sum of the concentration partitioned in the gas phase (CAH) and 
the concentration remaining in the aqueous phase (CA). 
xviii 
 
TC = CAH + CA 
Henry’s law states that the mole fraction of a dissolved gas (Xg) is equal to the 
partial pressure of the gas (pg) at equilibrium divided by Henry’s law constant (H). 
Gas solubility coefficients are used to calculate Henry’s law constant. 
Xg = Pg/H 
After manipulating equations and substituting volumes of each phase, the molar 
concentration of water (55.5 mol/L) and the molecular weight of the gas analyte 
(MW), a final equation is solved for. 
TC = [(55.5 mol/L)* Pg/H*〖10〗^3 mg/g] + ([Vh/((Vb-Vh))]* 
Cg*MW(g/mol)/22.4(L/mol) *[273K/((T+273K)]* 〖10〗^3 mg/g) 
Where Vb is the bottle volume and Vh is the volume of headspace. Cg is the 
volumetric concentration of gas. 
 
Headspace Sampling 
Sampling from the vapour phase, which is on top, of a sample container which 
contains the liquid or solid sample. Sampling may be conducted at room temperature 
or higher temperature depending on the volatility of the analyte molecules.  
 
Isothermal Programming 
In isothermal programming, the temperature of the column is held constant 
throughout the entire separation.  The optimum column temperature for isothermal 
operation is about the middle point of the boiling range of the sample.  However, 
isothermal programming works best only if the boiling point range of the sample is 
narrow.  If a low isothermal column temperature is used with a wide boiling point 
range, the low boiling fractions are well resolved but the high boiling fractions are 
slow to elute with extensive band broadening.  If the temperature is increased closer 
to the boiling points of the higher boiling components, the higher boiling components 
elute as sharp peaks but the lower boiling components elute so quickly there is no 
separation.  
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Leachable 
Chemicals that migrate from the product-contact component into a formulated drug 
during normal storage/usage conditions. 
 
Liquid Stationary Phase 
A thin layer of liquid that coats the inside of the GC column and interacts with 
gaseous sample compounds. This layer is typically 0.25 – 3.0 µm in depth and may 
solubilise the analyte molecules but does not chemically react with analyte 
molecules. 
 
Linearity  
The linearity of an analytical procedure is its ability (within a given range) to obtain 
test results which are directly proportional to the concentration (amount) of analyte 
in the sample.  
 
Mass Spectrometry  
An analytical technique that helps identify the amount and type of chemicals present 
in a sample by measuring the mass-to-charge ratio and abundance of gas-phase ions. 
A mass spectrum is a plot of the ion signal as a function of the mass-to-charge ratio. 
 
Mobile Phase / Carrier Gas  
Moving gaseous phase that can carry the vaporised sample molecules through the 
column. In GC the mobile phase gas does not interact with the sample molecules but 
merely carries them through the column. 
 
Noise 
This is a measure of the short time variation of the baseline of a chromatogram. It 
can be caused by electric signal fluctuations, lamp instability, temperature 
fluctuations and other factors. It is usually measured as the distance from top of a 
small peak on the baseline to the bottom of the next peak. Noise is the factor which 
limits detector sensitivity. In trace analysis, the operator must be able to distinguish 
between noise spikes and component spikes. 
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Partition Coefficient (Log P)  
The ratio of concentrations of an un-ionised compound in the two phases of a 
mixture of immiscible solvents at equilibrium. Generally, the two solvents chosen are 
water (aqueous phase) and octanol (hydrophobic organic phase). The compound to 
be measured is added to the water/octanol system. If the compound is acidic or basic, 
the pH is adjusted to ensure the compound is neutralised. Once equilibrium has been 
achieved, the compound is quantified in each solvent, typically via UV-Vis and the 
logarithm of the concentration ratio is calculated. The measurement is expressed with 
the following equation: 
Log P = Log ([Analyte]octanol / [Analyte neutral]water) 
 
pH 
The pH of a solution is a measure of the acidity of the solution. It is defined as: 
pH = -log10 ([H3O
+
]) 
where [H3O
+
] is the concentration of hydronium ions in the solution. 
 
Photodiode Array (PDA) UV-Vis Spectrophotometer 
UV–Vis spectrophotometers that use PDA detectors are able to simultaneously 
analyse a full spectrum. 
 
pKa 
The pKa of a solution describes the acidity of that solution, based on the inherent 
properties of the acid involved and the concentration of that acid.  
pKa = −log₁₀(Ka)  
where Ka = [H+][A-]/[HA] 
           HA = acid  
           A- = conjugate base  
           H+ = aqueous proton  
 
Placebo 
A placebo is lab-scale product made as per the manufacturing procedure but with the 
omission of at least one active ingredient contained within the full formulation. It is 
used to determine if any baseline interference can be detected at the expected 
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retention time of the omitted active ingredient. When testing for leachables the 
placebo may refer to a freshly made product that hasn’t been subjected to possible 
causes of leachables and will most often be packaged in glass containers. 
 
Precision  
The precision of an analytical procedure expresses the closeness of agreement 
(degree of scatter) between a series of measurements obtained from multiple 
sampling of the same homogeneous sample under the prescribed conditions. 
Precision may be considered at three levels: repeatability, intermediate precision and 
reproducibility.  
Precision should be investigated using homogeneous, authentic samples. However, if 
it is not possible to obtain a homogeneous sample it may be investigated using 
artificially prepared samples or a sample solution.  
The precision of an analytical procedure is usually expressed as the variance, 
standard deviation or coefficient of variation of a series of measurements.  
Repeatability  
Repeatability expresses the precision under the same operating conditions 
over a short interval of time. Repeatability is also termed intra-assay 
precision.  
Intermediate precision  
Intermediate precision expresses within-laboratories variations: different 
days, different analysts, different equipment.  
Reproducibility  
Reproducibility expresses the precision between laboratories (collaborative 
studies, usually applied to standardisation of methodology). 
 
Quantitation Limit 
The quantitation limit of an individual analytical procedure is the lowest amount of 
analyte in a sample which can be quantitatively determined with suitable precision 
and accuracy. The quantitation limit is a parameter of quantitative assays for low 
levels of compounds in sample matrices, and is used particularly for the 
determination of impurities and/or degradation products.  
The quantitation limit can also be obtained from precision studies. For this approach, 
decreasing analyte concentrations are analysed repeatedly and the relative standard 
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deviation is plotted against the corresponding concentration (precision function). If a 
predefined limit is exceeded, the corresponding concentration is established as the 
quantitation limit However, in practice, due to the high variability of standard 
deviations the true precision function is much more difficult to draw unless a large 
number of concentrations is included. 
The QL can be specifically calculated using the actual precision of the analytical 
procedure at this concentration. The calculation is based on the compatibility 
between analytical variability and specification acceptance limits. QL can be 
regarded as the maximum true impurity content of the manufactured batch, i.e., as 
the basic limit 
 
 
AL = Acceptance limit of the specification for the impurity. 
s = Precision standard deviation at QL, preferably under intermediate or 
reproducibility conditions. AL and s equal same unit (e.g., percentage with respect to 
active, mg, mg/ml). 
Nassay = Number of repeated, independent determinations in routine analyses, as far 
as the mean is the reportable result, i.e., is compared with the acceptance limits. If 
each individual determination is defined as the reportable result, n=1 has to be used. 
tdf = Student t-factor for the degrees of freedom during determination of the 
precision, usually at 95% level of statistical confidence. 
 
Range  
The range of an analytical procedure is the interval between the upper and lower 
concentration (amounts) of analyte in the sample (including these concentrations) for 
which it has been demonstrated that the analytical procedure has a suitable level of 
precision, accuracy and linearity. 
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Resolution 
A characteristic of the separation of two adjacent peaks. It may be expressed 
according to the equation: 
RAB = 2 |dR(B) - dR(A)| 
                |w(B) + w(A)| 
where RAB is the resolution, dR(A) and dR(B) are the retention distances (time or 
volume) of each eluted component A and B, and w(A) and w(B) are the respective 
widths of each peak at its base. 
 
Retention Time (tR) 
The time taken after injection for the analyte molecules to reach the detector. This 
dependent on the column flow rate, column capacity, extra column dead volume and 
the retardation factor of the molecules on the stationary phase. 
 
Robustness  
The robustness of an analytical procedure is a measure of its capacity to remain 
unaffected by small, but deliberate variations in method parameters and provides an 
indication of its reliability during normal usage. 
 
Run Time 
The time it takes for a complete chromatography cycle, i.e. from the time the sample 
is injected onto the column, until all products have been eluted from the system. 
 
Selectivity (α) 
A quantity which describes the separation of two species (A and B) on the column 
using the capacity factor (k) 
α = k(B) / k(A) 
When calculating the selectivity factor, species A elutes faster than species B. The 
selectivity factor is always greater than one.  
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Specificity  
Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present. Typically these might include 
impurities, degradants, matrix. 
 
Split Injection 
This allows a portion of the injected sample to enter the column and the rest will be 
vented to waste. The split is carried out in the injection chamber just prior to the 
column entry. This is used so that the column will not be overloaded and hence allow 
sharp peaks to be obtained. 
 
Split Ratio 
The ratio of gas that flows through the column and the split line. 
Split Ratio = (Column Flow Rate / Total System Flow Rate)  
 
Splitless Injection 
All injected molecules are carried onto the column. 
 
Stationary Phase 
A static surface that may interact with the molecules of a sample as they travel 
through the column. In GC this may be a solid or a liquid. 
 
System Suitability 
System suitability testing is an integral part of many analytical procedures. The tests 
are based on the concept that the equipment, electronics, analytical operations and 
samples to be analysed constitute an integral system that can be evaluated as such. 
System suitability test parameters to be established for a particular procedure depend 
on the type of procedure being validated.  
 
Temperature Programming 
In the temperature programming method, the column temperature is either increased 
continuously or in steps as the separation progresses.  This method is well suited to 
separating a mixture with a broad boiling point range.  The analysis begins at a low 
temperature to resolve the low boiling components and increases during the 
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separation to resolve the less volatile, high boiling components of the sample.  Rates 
of 5-7°C/minute are typical for temperature programming separations.  
 
Theoretical Plates (N) 
The number of theoretical plates is an index used to determine the performance and 
efficiency of columns. It is calculated using the below equation 
 
where tr = retention time and W = peak width. 
Alternatively, efficiency can be calculated using: 
  
where tr = retention time and W0.5 = peak width at half peak height. 
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Chapter 1: An Introduction to Container Closure Systems and Testing of 
Leachables in Pharmaceutical Products 
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1.1 Introduction 
Health systems rely on the continuous availability of safe, affordable 
pharmaceuticals (medicines, vaccines, diagnostics, and other medical supplies) of 
assured quality (Strengthening Pharmaceutical Systems 2011). It is the job of 
pharmaceutical companies to ensure that medicines and drugs are supplied free of 
contaminants, poisons, toxins and leachables. With the global pharmaceuticals 
market worth US$300 billion a year, the figure is expected to rise to US$400 billion 
within three years (World Health Organisation 2015). One common source of 
contaminants however, is the leaching of chemicals from the packaging into the drug 
product.  
The packaging components that hold and protect the drug product are known as the 
container closure system and include bottles, ampoules, vials, stopper lids, screw 
caps, stopper overseals, cardboard containers, plastic trays, paper inserts, overwraps 
and labels. The components can be divided mainly into primary and secondary 
packaging components with primary components being any of those in direct contact 
with the drug product and secondary components those that will never be in contact 
with the drug product (FDA 1999).  
The primary container’s chief purpose is to protect the drug product throughout its 
handling and storage. Most drug product primary components comprise of a bottle 
and cap, pouch or a blister that may be made from a variety of materials, including 
plastic, glass, metal, and laminated flexible materials. Primary container components 
must meet the requirements set out by the Food and Drug Administration (FDA) and 
the United States Pharmacopeia (USP). 
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Figure 1.1: An Example of Primary Packaging Components (Gerresheimer 2015)  
 
Although many types of materials can be used in a primary container closure system, 
the three most common are glass, polymers and elastomers. One may expect the 
manufacturer of any component of a container closure system to be able to provide a 
complete list of the formulation and process used to manufacture the component, but 
this may not always be the case. The two main reasons for manufacturers not 
providing this information are: 
1. The manufacturer may consider the information to be proprietary or the 
manufacturer may not have the information. 
2. The manufacturers of polymer container closure systems may use upstream 
suppliers that do not place strict controls over their processes. 
For example, a resin manufacturer will set specifications for their product on its 
physical characteristics only and then sell the same resin to a manufacturer of a 
pharmaceutical container closure system and a manufacturer of lawn furniture. In 
this example, the resin manufacturer may not have needed to keep accurate records 
on the amounts and type of antioxidants used as long as the resin met the 
manufacturer’s specifications, but these antioxidants do have the potential to leach 
into a drug product (NSF International 2014).
 
The secondary container components may be divided into critical and non-critical. A 
critical component such as a pouch may contain a primary component and provide 
protection against such things as light, gas and moisture that the primary component 
could not. It is a vital part of the container closure system for product stability. The 
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most common type of non-critical secondary component is the folding cardboard 
carton. Its job is to hold the primary container or containers for the final market and 
will usually contain any extras required for administering the drug product as well as 
paper inserts giving instruction on use. Generally labels and barcodes will be found 
on this component whilst it also serves as extra protection during storage and 
transport of the product.  
 
 
Figure 1.2: An Example of the Folding Cardboard Carton for Eye Drop Solutions 
                   (Drugs.com 2015)
 
 
Additional packaging may be required for the final exterior package and can include 
a case made of corrugated fibreboard and a wrapper. The final package will often be 
transported on wood pallets which are frequently treated with fungicide and have 
5 
 
been known to be the cause of previously seen leachables (Koschier et al 2011). All 
labels necessary for the National Wholesale Druggists' Association (NWDA) will be 
affixed to the exterior packaging (United States Pharmacopeia 37 2015, Good 
Packaging Practices).  
 
 
1.2 Extractables and Leachables 
 
Although every component of the container closure system is intended to protect the 
drug product from contaminants, they can invariably be the principal source of 
monomers and polymer additives such as antioxidants, plasticisers, stabilisers, dyes, 
metal catalysts and other harmful chemicals leaching into the drug product. 
Extractables and leachables are often mentioned concurrently. Extractables can be 
defined as chemicals that migrate from the product-contact component into a solvent 
at accelerated conditions (such as heat, time, pH, ionic strength, organic solvent 
content). Leachables are a subset of extractables. They are chemicals that migrate 
from the product-contact component into a formulated drug during normal 
storage/usage conditions (Feilden 2008).
 
The need to investigate extractables and track leachables is an important challenge 
faced by the pharmaceutical industry. Analytical methods are required to test for and 
track leachables but before that method development extraction studies need to be 
conducted to determine what extractables could become leachables over time. The 
European Agency for the evaluation of Medical Products (EMEA) and the U.S. FDA 
are increasing scrutiny on potential extractables and leachables in drug product 
container and closure systems. Recently, the FDA Food Safety Modernisation Act 
was updated with particular relevance for extractables stating that "A drug or device 
shall be deemed to be adulterated... if its container is composed, in whole or in part, 
of any poisonous or deleterious substance which may render the contents injurious to 
health” (Code of Federal Regulations 2015). This definition plainly highlights the 
need for extractable studies within regulatory expectations.  
Extraction studies are designed to mimic both intended use and worst-case-scenario 
models to identify the extractables and leachables that could migrate into the drug 
product. The toxicology of each potential leachable migration must also be 
established (Beierschmitt 2009; Northup 2008; Nicholas 2006; Osterberg 2005). A 
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toxicological study is conducted following extraction experiments performed on the 
packaging components and patient impact is evaluated. Extraction experiments are 
performed under exaggerated conditions of temperature and time in the laboratory 
using common, neat solvents that bracket the solvating power of the drug (Moffat 
2010). The formulation matrix is the preferred solvent as it replicates what is most 
likely to happen in the final marketed product. Reliable identification and sensitive 
analytical techniques such as Mass Spectrophotometry (MS), Gas Chromatography 
(GC) and Liquid Chromatography (LC) are essential in identifying extractables and 
possible leachables. 
Whilst these studies are performed during the development phase, the only way to 
truly measure potential extractables and leachables is over the shelf life of the 
product with applicable toxicological data to support. Two types of Biological 
Reactivity tests (in vivo and in vitro) are stipulated by the USP to assess the toxicity 
of possible extractables and leachables (United States Pharmacopeia 37 2015).  
 
Robust carcinogenic, mutagenic or genotoxic studies may not need to be performed 
throughout a stability study on every identified leachable if supporting data is already 
available. The molecular structure, known toxicity of a leachable or known toxicity 
of closely related compounds may be satisfactory to assess the safety threshold. 
Toxicologists may reference various databases such as INCHEM
®
 (International 
Programme on Chemical Safety 2015), ExPub
®
 (Chemical Hazard Information for 
EH&S Professionals 2015) and TOXNET
®
 (Toxicology Data Network, Untied States 
National Library of Medicine 2015) as part of their data search. 
When container closure systems are developed for a pharmaceutical product, various 
vendors will be screened by companies to assess suitability for each component. The 
toxicological and analytical data will ultimately be what decides the final selection 
(Laschi et al 2009; Corredor et al 2009; Ball 2007; Markovic 2009; Wakankar et al 
2010; Alarcon et al 2007a; Alarcon et al 2007b; Feilden 2008; Vega-Mercado 2004). 
Jenke et al (2007) outlines what is expected of the packaging component supplier 
and final product vendor. He defines a collaborative strategy between both parties to 
enable a knowledge sharing platform while protecting the confidential information 
belonging to each individual group. Separately, Pan et al (2008) and Castner et al 
(2009) suggest approaches using GC, LC, MS and Ultra Violet (UV) with 
Photodiode Array (PDA) for the determination of leachables in liquid drug. Further 
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evidence for leachable identification is used by Castner et al (2009) with Log D 
partitioning data based on the solution pH and analyte pKa. 
A typical extractable and leachable study plan can be seen in Figure 1.3. 
 
 
 
 
Figure 1.3: An Example of an Extractable and Leachable Study Plan  
                    (Evans Analytical Group 2015) 
 
The study needs to be able to detect substances of concern from process equipment 
and the container closure system and then be able to track them throughout the 
product’s shelf life. The European Agency for the evaluation of Medical Products 
(EMEA) Guideline states that “ It should be determined whether any of the 
extractables are also leachables present in the formulation at the end of the shelf life 
of the product or to the point equilibrium is reached if sooner” (Cartwright et al 
2010).  
First and foremost Analytical Evaluation Thresholds (AETs) need to be calculated. 
This is gained by establishing the Safety Concern Threshold (SCT) set out by the 
Product Quality Research Institute (PQRI) relevant to the product. From the SCT, the 
sample preparation and daily exposure are assessed and an AET value generated. 
Extractables can then be tested for and put forward for toxicological assessment. 
Based on the levels of extractable(s) observed and related toxicological evaluation, 
method(s) can be established and validated for long term leachable evaluation 
(Product Quality Research Institution 2006).  
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A typical leachable study to monitor potential migratory chemical species throughout 
the shelf life of the product might be as per Table 1.1:  
 
Time (months)  0 1  2  3  6  9  12  18  24  36  
Real Time Data  x        x  x  x  x  x  x  x  
Accelerated data     x  x  x  x  x  x          
Table 1.1: A Typical Leachables Test Schedule  
 
Real time data is based on the normal storage conditions of the product whereas 
accelerated data tests the drug product at higher temperatures and/or humidity. If a 
correlation between extractable and leachable profiles can be established, control of 
leachables could be accomplished via testing and limits on extractables. 
 
 
1.3 Leachables in Industry 
 
Over the years, there have been many incidents involving chemicals leaching into 
foods and drug products from container closure systems. In 2008, Canada banned the 
use of the chemical bisphenol A (BPA) in polycarbonate baby bottles while some 
polycarbonate bottle manufacturers voluntarily eliminated BPA from their products 
(Wang et al 2010). Numerous studies have shown that BPA acts as an endocrine-
disruptor in animals, including early onset of sexual maturation, altered development 
and tissue organisation of the mammary gland and decreased sperm production in 
offspring. In one particular study on the effects of BPA, Karin B. Michels, Associate 
Professor of Epidemiology at Harvard School of Public Health (HSPH) and Harvard 
Medical School said “We found that drinking cold liquids from polycarbonate bottles 
for just one week increased urinary BPA levels by more than two-thirds. If you heat 
those bottles, as is the case with baby bottles, we would expect the levels to be 
considerably higher. This would be of concern since infants may be particularly 
susceptible to BPA’s endocrine-disrupting potential” (Carwile et al 2009). 
Carbon black, common in tyres and industrial rubber products is used as an additive 
to make rubber supple. In the 1980s it was shown that cancer-causing polynuclear 
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aromatic hydrocarbons leached from carbon-black-containing rubber used in 
products such as asthma inhalers and baby-bottle nipples (Grilli 2015). It still has 
many uses including pigmentation and UV protection but is no longer used as part of 
container closure systems. 
Plastic is by far the most common packaging material and leachables can include 
everything from additives used to make plastic strong or malleable, to leftover 
monomer building blocks. However, leachables can be produced from all sorts of 
packaging materials. The waxy wrapping that lines popcorn bags and is used to wrap 
burgers has been shown to leach polyfluoroalkyl phosphoric acids (PAPs). A study 
by Scott Mabury, a University of Toronto chemistry professor, described how these 
PAPs can accumulate in the body after being absorbed by humans (D'eon et al 2010). 
They can then become carcinogenic and hormone disrupting when metabolised and 
turned into perfluorinated carboxylic acids (PFCAs). European, Canadian and US 
governments now intend to extensively track PAPs and their dangers when exposed 
to humans.  
Inks used for printing are also a major concern. In 2005, Nestle were forced to recall 
millions of litres of infant formula across Europe when isopropilthioxanthone (ITX), 
a printing-ink component, was found in the product. The European Food Safety 
Authority (EFSA) had found that levels of ITX in the product did not pose a health 
risk but that did not prevent a number of European countries demanding the recall 
such is the fear of a consumer backlash. The chemical’s use in the formula’s 
packaging has since been phased out by Tetra Pak, the firm that supplied the 
packaging to Nestle (Laksin et al 2007). 
 
Recently in Germany, a printing ink component, 4-methylbenzophenone had been 
found by the EFSA to be leaching from the outside of the cardboard box holders of 
chocolate muesli into the cereal. 4-methylbenzophenone is a photo-initiator, a highly 
photoactive compound included in the formulations of UV curing printing inks 
usually applied to packaging surfaces (Luis Aparicio et al 2015). It has similar 
properties to benzophenone and is often partly left behind during the printing 
process. If a functional barrier like aluminium foil is not present and due to its high 
volatility 4-methylbenzophenone may migrate from the cardboard through any 
plastic barriers and into the food (Choi et al 2002; Pastorelli et al 2008; Song et al 
2003; Feigenbaum et al 2005). The EFSA concluded that based on its knowledge on 
the toxicity of benzophenone, people should not be at risk to short term consumption 
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of cereals contaminated by 4-methylbenzophenone. However, if the chemical’s use 
was to be continued, more data would need to be gathered for a full risk assessment 
(European Food Safety Authority 2009).   
Other examples of leaching were described at a 2009 leachables convention in 
Barcelona by Ingrid Markovic, a regulator at FDA’s Centre for Drug Evaluation & 
Research. She discussed how two different pharmaceutical companies encountered 
problems with the packaging of their liquid protein drugs. In the first case, a solvent 
from the epoxy glue used to stick a syringe barrel and metal needle together had 
leached into the drug product and aggregated the protein into clumps. In the other 
case, tungsten oxide salt residue had leached into the drug product after using a 
tungsten filament on the syringe needle which again led to aggregation of the protein 
(Everts 2009).
 
 
 
1.4 Tampoprinting 
 
Pad printing, also known as tampoprinting, was first developed and used to print 
watch dials in the Swiss watch industry (TAMPOPRINT AG 2015). Machines were 
manually operated and used pads made from gelatine and oil based inks that were 
slow drying. The process was developed further by the Germans during the 1960s 
with the use of mechanical machines and pads made from silicone rubber. Inks were 
also improved which meant that printing could be achieved on many different 
materials and products.  
Nowadays, there is a large variety of inks available meaning nearly all materials can 
be printed on and due to the inks quick drying properties very detailed designs of 
many different colours can be accomplished. All shapes of products can also benefit 
from modern day tampoprinting thanks to the suppleness and elasticity of the 
silicone rubber pads.  
It is most commonly used to print on plastics, metals and ceramics for use in the 
industrial, pharmaceutical, automotive, white goods and retail markets (Tampo 
Limited 2015). 
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The tampoprinting cycle begins by filling the engraved area of a printing plate, 
known as the cliché, with low viscosity ink. The low viscosity allows the ink to flow 
evenly. 
The surface of the cliché is then cleared of excess ink leaving just the engraved area 
with any ink. The transfer pad then presses over the engraved part of the cliché in an 
even, rolling action, pushing air out of the way as it compresses.  As the solvents 
evaporate from the top of the ink within the engraved surface of the cliché, the 
increased stickiness of the exposed ink surface enables it to adhere to the pad. 
When the pad moves away from the cliché the exposed surface of the ink film on the 
pad starts drying making it stickier so when the pad is pressed onto the surface of the 
product being imprinted, the stickiness of the ink's surface allows the ink to leave the 
pad and now adhere to the product.  The pads design means the image can be rolled 
onto the product ensuring that air is not trapped and good image transfer can be 
achieved.  
Lastly, the pad moves from the product surface back to its starting position ready for 
the following transfer (ACC Silicones 2015). 
   
12 
 
 
Figure 1.4: A Schematic of the Tampoprint Process (PDS International Limited 
2015) 
 
The characteristics of each component involved in the process are very important.  
Hardness is the defining characteristic when choosing the material from which to 
make the cliché. The harder the material, the longer it will last so a photopolymer 
plate is popular for short to medium production runs whereas steel plates are more 
common in medium to long runs. For very long runs a thick steel cliché is required. 
Engravings in the cliché are usually 25 to 30 microns in depth allowing a dried ink 
film thickness of 2 microns up to 20 microns depending on the depth of colour 
required.  
The shape, hardness and surface of the pad will determine its ability to transfer an 
image effectively. Any changes in the hardness of the pad can dramatically affect 
print quality. Harder pads are generally more efficient in transferring ink but will not 
compress properly if too hard. A good balance is therefore always required to ensure 
high quality printing (ACC Silicones 2015). 
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Inks used for tampoprinting will generally be a mixture of a coloured ink with the 
addition of a thinner and a hardener. The thinner is made up of solvents that 
influence the flow and viscosity of the ink as well as its ability to adhere to the pad 
and transfer from the pad to the work piece. The thinner will also affect the drying 
speed of the ink with quick and slow drying solvents available. The hardener is 
added to the mixture to create a better consistency and allow the ink and thinner to 
form effectively. 
There are many benefits of tampoprinting. They include high levels of quality with 
excellent repeatability due to microprocessor controlled machines and the ability to 
turn plain pieces of work into more visually pleasing pieces and hence increase their 
value. The ability to use an assortment of coloured inks without the need for drying 
is an immense time saver. Also, machines are generally very easy to operate with 
few parts to change whilst a wide variety of materials of all shapes and sizes can be 
printed on (Irish Micro Moulding 2015). 
 
 
1.5 Tampoprinting at Allergan 
 
In Allergan tampoprinting is performed on unit dose (UD) vials only. The UD vials 
are made from low density polyethylene (LDPE), a virtually unbreakable yet quite 
flexible and chemically unreactive plastic (Dynalab 2015). They arrive at the 
tampoprint line filled with product and sealed ready to be labelled.  
 
 
Figure 1.5: UD Vials after Tampoprinting  
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The vials are sorted and stacked on the belt of the machine before lasers ensure they 
are correctly aligned and in the correct position for printing. The printing machine 
consists of two printers; the first printer that the vials arrive at applies the lot number 
and expiry of the product plus a 2D code that is unique to each vial. The vials 
continue along the machine to the next printer which performs the tampoprinting. A 
thick steel cliché is used due to the high volume of printing with engravings that are 
etched using a laser for high precision and definition. The ink mixture is made up 
using 10 parts ink, 1 part hardener and 6 parts thinner and mixed for 12 hours before 
use. The vials are tampoprinted with the ink mixture on the opposite side from the 
initial printing before travelling through an infrared drying station to cure the ink and 
prevent smudging. The vials are then stacked and prepared for packaging.  
Over time it has been observed that solvents present in the ink thinner can leach from 
the Tampoprint ink into the product. Tampoprint ink thinner purchased from 
Tampoprint International, is routinely qualified as a laboratory reference standard 
(LRS) within Allergan. This reference standard is utilised by analytical laboratories 
as a leachables identification solution (LIS) in GC finished product assays to identify 
the tampoprint related container-closure leachables cyclohexanone and PGMEEA. 
Historically, test results of the tampoprint ink thinner had detected a mixture of 
approximately 20:80 (cyclohexanone:PGMEEA) by area percent but recently a third 
component was identified in new lots of tampoprint ink thinner. New lots of the 
tampoprint ink thinner were consequently tested by proton/carbon nuclear magnetic 
resonance (NMR) and results revealed the third compound was present at 
approximately 20% (by proton mole ratio) in the ink thinner in addition to the 
expected proton signals for cyclohexanone and PGMEEA which were seen at 
approximately 30% and 50% respectively. GC tests were then conducted that showed 
the new component to be present at approximately 15% by area percent while 
cyclohexanone had increased from 20% to 33% and PGMEEA had decreased from 
80% to 52%.  
Tampoprint International was notified that a third component had been observed in 
new lots of the ink thinner and they verified that the component was PGMMEA. 
Going forward it is important that any methods used for the analysis of Tampoprint 
related leachables assesses the presence of all three ink thinner components; 
cyclohexanone, PGMMEA and PGMEEA. The chemical structures and properties 
for each leachable can be seen in Table 1.2. 
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Table 1.2: Chemical Structure of Cyclohexanone, PGMMEA and PGMEEA 
Name Properties Analyte Structure 
Cyclohexanone 
(Pubchem 2015) 
 
Molecular Weight = 98.143 g/mol 
Molecular Formula = C6H10O 
Boiling Point = 156˚C 
Melting Point = -31˚C 
  
 
 
Propylene glycol 
monomethyl ether 
acetate (PGMMEA) 
(Haltermann 2015) 
 
Molecular Weight = 132.16 g/mol 
Molecular Formula = C6H12O3 
Boiling Point = 146˚C 
Freezing Point = -66˚C 
  
 
 
Propylene glycol 
monoethyl ether 
acetate (PGMEEA) 
(NIOSH 2015) 
 
Molecular Weight = 146.184 g/mol 
Molecular Formula = C7H14O3 
Boiling Point = 160˚C 
Melting Point = -89˚C 
 
 
 
 
 
 
 
1.6 Analysis of Leachables by GC and HS-GC 
 
Leachables in final product are most commonly detected using GC and LC 
techniques with GC utilised for the quantitation of volatiles and LC employed for 
non-volatiles. A testing schedule for every lot produced in Allergan is created from 
when the final product is packaged and released right through its shelf life to final 
expiry usually at 3 to 6 month intervals. The packaging of the product will be the 
main consideration in developing test methods to track possible leachables that can 
appear during the lifetime of the product. If certain components such as those used in 
the Tampoprint ink thinner are known to leach into the product then a method is 
required to track those leachables. As the tampoprint related components are known 
volatiles the best technique to use is GC. In Allergan, the two main types of GC in 
use are direct injection GC and headspace GC. 
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Figure 1.6: A Schematic of a Typical GC System (Chromedia 2015) 
 
In direct injection GC the sample is transferred from a vial to the GC system via a 
micro syringe injector. Generally no more than a few microliters of the sample are 
required for injection. The injector port is typically set to a temperature about 50°C 
hotter than the boiling point of the least volatile component in the sample. This 
ensures vaporisation and only a gas form of the sample reaches the chromatographic 
column.  
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Figure 1.7: The Split/Splitless Injector (Sheffield Hallam University 2015) 
 
The sample is carried along through the system via the mobile phase which is a 
chemically inert gas such as helium or nitrogen. Hydrogen is also commonly used, 
however due to safety issues arising from its flammability, none of the GC systems 
within Allergan are set up to use Hydrogen as a carrier gas. It is therefore left to 
decide between Helium and Nitrogen. The most obvious choice is Helium due to its 
superior properties in diffusion speed. The diffusion speed of Hydrogen is about 4 
times higher than that of Nitrogen allowing for faster chromatography and better 
separation (Grob 1997).  
Once at the column the components in the sample can be separated by the column. 
The most common type of column is a capillary column which is made up of a thin 
fused silica tube and a polyimide coating. They are strong yet flexible with the ability 
to be wound into coils and have low reactivity. The inside of the tube is coated with a 
chemically bonded stationary phase which interacts with the components in the 
sample. The other column option is a packed column. They are usually stainless steel 
and shorter with a larger diameter than capillary columns. They have the advantage 
of a higher sample capacity and are more durable whilst also costing less.  However, 
for analysis of low ppm concentrations the capillary column is far superior to the 
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packed column. The capillary column has many more theoretical plates allowing for 
much better detection and separation of peaks. Capillary columns also heat and cool 
to temperature faster within the oven and require less gas to the detector. 
 
 
 
 
 
 
Figure 1.8: A Fused Silica GC Column (Dot-Red Analytical 2015) 
 
 
There are two basic types of fused silica capillary columns; the Wall Coated Open 
Tubular (WCOT) column and the Porous Layer Open Tubular (PLOT) column. 
WCOT columns are most commonly used for GC analysis and consist of a liquid 
film coated to the deactivated wall of the column. In PLOT columns the stationary 
19 
 
phase is a solid substance, most commonly Divinylbenzene and Aluminia, that is 
coated to the column wall and used for very specific analysis (Agilent 2015). 
 
 
 
 
 
Figure 1.9: Schematic of Wall Coated Open Tubular (WCOT) column and the 
Porous Layer Open Tubular (PLOT) Column (UC Davis ChemWiki 2015) 
 
The column is set up in the GC oven which dictates the temperature of the column, 
the lower the temperature the slower the sample components take to travel through 
the column and the lower the quality of separation between the components. 
However, if the temperature is too high the sample components travel through the 
column too quickly and are unable to interact with the stationary phase. Most GC 
methods will therefore incorporate a temperature gradient whereby the column oven 
is increased in temperature over a certain time allowing full separation of 
components with shorter run times. Components with higher boiling points will be 
seen later than those with lower boiling points as the oven temperature rises. The 
column length is also an important factor with shorter columns providing shorter run 
times but poorer separation to longer columns. The speed that the mobile phase flows 
through the column also needs to be considered, if it flows too fast the run time is 
again reduced but there is less time for the sample components to interact with the 
stationary phase and poor separation can result (UCLA 2014).   
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At the end of the column the mobile phase carrying the sample reaches the detector 
with sample components arriving at varying times depending on how long they were 
retained on the column. The best type of detector for the analysis of organic 
compounds is the flame ionisation detector (FID) due to its high sensitivity, ease of 
use and robustness. There is also very low background noise as minimal ions are 
created when carbon is absent. Hydrogen and air are pumped through the detector 
and mix with the sample before igniting. Electrons and ions are produced from any 
burning organic compounds and conduct electricity with the current measured by the 
detector via a collector electrode above the flame. The changes in current can be 
visualised as a chromatogram and allows the sample components to be quantitated 
using software such as Empower (Sheffield Hallam University 2015).  A diagram of 
the FID can be seen in Figure 1.7. 
 
 
 
 
Figure 1.10: An FID Detector (Sheffield Hallam University 2015) 
 
Headspace GC differs from direct injection GC in how the sample is injected onto 
the column. The sample vials used for headspace GC are typically 10 to 20 mL in 
volume compared to the smaller 2 mL vials used for direct injection GC. Typically, a 
stipulated amount of sample is added to a headspace vial occupying less than 50% of 
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the vial volume. The vial is then heated in a vial oven allowing any volatiles within 
the sample to move into the gas portion, also known as the “headspace” of the 
sample vial. This means that volatile sample components can be separated from non-
volatile sample components within the vial. Once a state of equilibrium is reached 
between the gas phase and sample phase a portion of the gas will be removed from 
the vial and injected onto the column. Once the sample reaches the column the same 
process takes place as that previously described for direct injection GC. 
Headspace GC is therefore an effective technique for the determination of volatile 
components within a complex sample matrix that would otherwise require sample 
extraction or be difficult to directly analyse (Labhut.com 2015). 
   
 
  G = The gas phase/headspace 
  The gas phase/headspace sits above the sample phase and 
is  
  occupied by sample volatiles once the vial is sealed. 
 
  S = The sample phase 
  Volatiles within the sample phase move between the 
headspace   
  and the sample phase until a state of equilibrium is 
reached as   
  depicted by the arrows. An aliquot of the headspace is then  
  removed and injected onto the column. 
 
Figure 1.11: Phases of the Headspace Vial (Labhut.com 2015) 
 
Headspace GC often employs a standard addition method. This is a universal 
procedure in headspace measurement and has been recommended since the early 
days of quantitative headspace analysis. The determination is carried out in an 
identical matrix; thus, no response (calibration) factors are needed for the calculation. 
Peak area and amount of the analyte are proportional; from this relationship, one can 
then directly calculate the original amount present (Kolb 2006). 
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1.7 Summary/Concluding Remarks 
 
The objectives of this thesis are to develop and validate methods capable of the 
detection and quantitation of three known leachables in two separate ophthalmic 
formulations. Cyclohexanone, PGMMEA and PGMEEA are solvents from the ink 
thinner used during the Tampoprint process when labelling the LDPE vials that 
contain the ophthalmic solutions. Once packaged, these solvents are known to leach 
from the outside of the vial into the solution. It is a requirement for companies to 
track any leachables that may be present within their products. Hence, these 
developed methods will be used for the duration of each products shelf life to ensure 
that the amount of each leachable remains at a safe level below its threshold limit. 
Each method will also be capable of detecting unknown volatiles from the container 
closure system that may show up during the shelf life of each product.   
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2.1 Introduction 
 
Although there are a number of published papers to show cycloheaxanone, propylene 
glycol monoethyl ether acetate (PGMEEA), and propylene glycol monomethyl ether 
acetate (PGMMEA) have been tested by GC (Ulsaker et al 1977; Dugard et al 1984), 
there is very little to show that there are any methods available to test the three 
analytes together. 
This method uses direct injection gas chromatography to detect and quantitate the 
concentrations of the Tampoprint-related leachables cyclohexanone and PGMEEA, 
and PGMMEA. It also estimates the concentration of other potential volatile and 
semi-volatile container closure leachable components by comparison of gas 
chromatographic (GC) profiles of ophthalmic solution samples stored in plastic 
container/closure systems versus identical samples stored in glass (or unlabelled 
plastic containers) as a control. Comparison of these two chromatographic ‘finger 
prints’ forms the basis of evaluating the presence of volatile and semi-volatile 
leachables. If gas chromatographic profiles are the same for test and control samples, 
it is strong evidence that no such leachables are present in the ophthalmic solution. 
The Tampoprint-related leachables that are seen in Product Z have not previously 
been tested and thus a new method is required. 
This method will be validated in accordance with the current USP Category II 
(United States Pharmacopeia 37 2015) for cyclohexanone, PGMMEA and PGMEEA. 
The validation will also meet all requirements under ICH guidelines Q2 (R1) 
(International Conference of Harmonisation 2005). 
The proposed method validation tests that will be carried out on the specified 
leachables cyclohexanone and PGMMEA are: accuracy, linearity, range, precision 
(repeatability and intermediate), specificity, detection limit (DL), quantitation limit 
(QL), robustness and standard stability. As no PGMEEA standard is available, the 
validation tests that will be carried out on the specified leachable PGMEEA are: 
precision (repeatability and intermediate), robustness and specificity. Since there is 
no standard material available for PGMEEA and due to its structural similarity 
PGMMEA will be used to estimate PGMEEA in samples. 
 
 
 
33 
 
2.2 Experimental 
 
2.2.1 Initial Development 
An initial investigation into previously validated leachables methods provided a 
number of options for sample preparation and GC conditions. Although the 
leachables for this particular project had not been tested before it was believed that 
their properties were ideal for one particular method which utilised a DB5 GC 
column (5%-phenyl 95%-dimethylpolysiloxane). The boiling point range of 146 -
160˚C for the three leachables lies in the middle of the recommended temperature 
range of the DB5 column. Also the DB5 column is a low polarity column and is ideal 
for the separation of the relatively low polarity leachables. A sample preparation of 
1:1 using acetonitrile as sample and standard diluent was to be utilised. 
An external toxicological assessment was performed for each of the proposed 
leachables. The report concluded that each of the leachables were safe up to a limit of 
20 ppm. As the sample preparation required a dilution of 1:1, standards were required 
to be prepared at a final working concentration of 10 ppm. 
Standards ranging in concentration from 0.5 to 30 ppm were made and tested on the 
DB5 column utilising the following GC conditions; an oven temperature programme 
starting at 35˚C for 8 minutes before ramping at 15˚C/minute and holding at 245˚C 
for 10 minutes. Total run time was 32 minutes with a constant flow of helium at 7.0 
mL/minute. The inlet was set at 250˚C with a purge flow of 25 mL/minute for 1.5 
minutes. The detector was set at 250˚C and the makeup gas was helium at 30 
mL/minute. Hydrogen was used for the fuel flow at 30 mL/minute and air was used 
for the oxidiser flow at 300 mL/minute. 
The chromatograms were assessed and showed good peak shape and resolution.  
 
2.2.2 Reagents 
Analytical grade cyclohexanone and propylene glycol monomethyl ether acetate 
(PGMMEA) were purchased from Sigma Aldrich (Poole, UK). Tampoprint thinner, 
VDL-1015 was purchased from Tampoprint (Stuttgart, Germany).  
Solvents used included acetonitrile (HPLC grade) which was purchased from 
Labscan (Dublin, Ireland). Ultrapure water was obtained from a millipore Milli-Q 
34 
 
water purification unit (Millipore, Bedford, MA, USA).  High purity grade 
compressed air, hydrogen and helium were purchased from BOC (Surrey, UK). 
 
2.2.3 Instrumentation and Apparatus 
An Agilent 7890 GC system with FID and Agilent DB-5 column, 30 m x 0.53 mm x 
1.0 µm film thickness (part number 125-503J) were utilised for all testing. A 
deactivated fused silica tubing guard column (Phenomenex, part number 7CK-G000-
00-GZK) was attached to the column. Graphite ferrules by Agilent were used to 
attach the column to the GC system (part number 5080-8773). GC auto injector vials 
and caps were from Agilent (part number 5182-0866). The liner was an Agilent 
capillary single taper splitless liner, 4 mm, deactivated borosilicate glass (part 
number 5062-3587). The injector septa and o-ring were also from Agilent (part 
number 5183-4757 and 5188-5365 respectively). The GC utilised an oven 
temperature programme starting at 35˚C for 8 minutes before ramping at 
15˚C/minute and holding at 245˚C for 10 minutes. Total run time was 32 minutes 
with a constant flow of helium at 7.0 mL/minute. The inlet was set at 250˚C with a 
purge flow of 25 mL/minute for 1.5 minutes. The detector was set at 250˚C and the 
makeup gas was helium at 30 mL/minute. Hydrogen was used for the fuel flow at 30 
mL/minute and air was used for the oxidiser flow at 300 mL/minute. All settings 
were controlled using Empower software. 
Glassware was provided by Schott (Mainz, Germany) and consisted of 0.5 mL, 1 
mL, 2 mL, 3 mL, 5 mL and 10 mL volumetric pipettes (Class A) as well as 10 mL, 
20 mL, 50 mL and 100 mL amber volumetric flasks (Class A). All glassware was 
washed in a Hamo LS2000 glass washer using RBS 50 pF detergent and RBS R 60 
acid. Both the detergent and acid were purchased from Chemical Products R. 
Borghgraef S.A. (Brussels, Belgium). 
Pasteur pipettes made from low density polyethylene were obtained from VWR (part 
number 16001-170). 
 
2.2.4 Standard Preparation 
A stock standard (SS) was prepared by pipetting 1 mL of cyclohexanone and 1 mL of 
PGMMEA into a 100 mL amber volumetric flask containing approximately 70 mL 
of acetonitrile. The volumetric flask was brought to volume with acetonitrile and 
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mixed using a magnetic stirrer for 15 minutes. Nominal concentration was 9470 ppm 
for cyclohexanone and 9700 ppm for PGMMEA. 
An intermediate standard (IS) was prepared by pipetting 1 mL of the stock standard 
solution into a 100 mL amber volumetric flask, containing approximately 70 mL of 
acetonitrile. The volumetric flask was then brought to volume with acetonitrile and 
mixed using a magnetic stirrer for 15 minutes. Nominal concentration was 94.7 ppm 
for cyclohexanone and 97.0 ppm for PGMMEA. 
A working standard (WS) was prepared by pipetting 10 mL of the intermediate 
standard solution into a 100 mL amber volumetric flask, containing approximately 
70 mL of acetonitrile. The volumetric flask was brought to volume with acetonitrile 
and mixed using a magnetic stirrer for 15 minutes. Nominal cyclohexanone 
concentration was 9.47 ppm. Nominal PGMMEA concentration was 9.70 ppm. A 
typical chromatogram of the working standard solution can be seen in Figure 2.1. 
Working standard concentrations are based on the cyclohexanone density of 0.947 
g/mL and the PGMMEA density of 0.970 g/mL. 
 
Figure 2.1: GC-FID of WS (cyclohexanone 9.47 ppm; PGMMEA 9.70 ppm). GC Conditions: Agilent 
7890 GC FID, Agilent Capillary DB-5 column, 30 m x 0.53 mm x 1.0 µm film thickness, guard column 
(Phenomenex deactivated fused-silica tubing), splitless injection, injection volume 1L. The GC oven 
temperature programme starting at 35˚C for 8 minutes before ramping at 15˚C/minute and holding at 
245˚C for 10 minutes. Total run time was 32 minutes with a constant flow of helium at 7.0 mL/minute. 
Injection temperature 250˚C, detector temperature 250˚C. Hydrogen: Air flame (30:300). 
A PGMMEA Detector Sensitivity Solution (DSS) was prepared by pipetting 2 mL of 
the working standard solution into a 20 mL amber volumetric flask containing 
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approximately 10 mL of acetonitrile before diluting to volume with acetonitrile. The 
solution was mixed using a magnetic stirrer for 15 minutes. Nominal PGMMEA 
concentration was 0.97 ppm.  
A cyclohexanone detector sensitivity solution (DSS) was prepared by pipetting 0.5 
mL of the working standard solution into a 20 mL amber volumetric flask, 
containing approximately 10 mL of acetonitrile before diluting to volume with 
acetonitrile. The solution was mixed using a magnetic stirrer for 15 minutes. 
Nominal cyclohexanone concentration was 0.24 ppm.  
A leachable identification working solution (LIS) was prepared by pipetting 1 mL of 
the tampoprint thinner solution into a 100 mL amber volumetric flask containing 
approximately 70 mL of acetonitrile. The volumetric flask was then brought to 
volume with acetonitrile and mixed using a magnetic stirrer for 15 minutes. 1 mL of 
this solution was pipetted into a 50 mL amber volumetric flask, containing 
approximately 30 mL of acetonitrile. The volumetric flask was then brought to 
volume with acetonitrile and mixed using a magnetic stirrer for 15 minutes. 5 mL of 
this solution was then pipetted into a 50 mL amber volumetric flask, containing 
approximately 30 mL of acetonitrile. The volumetric flask was then brought to 
volume with acetonitrile and mixed using a magnetic stirrer for 15 minutes. See 
Figure 2.2 for a typical chromatogram of the leachable identification working 
solution.  
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Figure 2.2: GC-FID of LIS. GC Conditions: Agilent 7890 GC FID, Agilent Capillary DB-5 column, 
30 m x 0.53 mm x 1.0 µm film thickness, guard column (Phenomenex deactivated fused-silica tubing), 
splitless injection, injection volume 1L. The GC oven temperature programme starting at 35˚C for 8 
minutes before ramping at 15˚C/minute and holding at 245˚C for 10 minutes. Total run time was 32 
minutes with a constant flow of helium at 7.0 mL/minute. Injection temperature 250˚C, detector 
temperature 250˚C. Hydrogen: Air flame (30:300). 
 
A blank was used to identify any system related peaks unrelated to the sample. The 
blanks consisted of GC vials filled by pasteur pipette with the acetonitrile that was 
used to dilute the samples and standards.  
 
2.2.5 Sample Preparation 
2.2.5.1 Product Z Control Samples  
Product Z control samples are Product Z samples stored in glass containers, glass 
ampoules, unlabelled bottles or bottles with blank labels depending on the nature of 
the leachable study. Product Z control sample was pooled into a glass container from 
a number of glass ampoules. A 1:1 dilution of the control sample was then performed 
with acetonitrile in a volumetric flask. The volumetric flask was then vortexed for 15 
seconds before leaving the volumetric flask to stand for 15 minutes to allow the 
contents to settle. (A white precipitate became visible at the base of the volumetric 
flask.) A GC vial was then filled from the volumetric flask using a pasteur pipette 
ensuring no precipitate was removed from the bottom of the flask.  
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2.2.5.2 Product Z Test Samples 
Product Z test sample was prepared in the same manner as the control sample by 
pooling sample from final product plastic bottles (with Tampoprint labelling) into a 
glass container. See Figure 2.3 for a typical chromatogram of a Product Z sample.  
 
Figure 2.3: GC-FID of Product Z Control. GC Conditions: Agilent 7890 GC FID, Agilent Capillary 
DB-5 column, 30 m x 0.53 mm x 1.0 µm film thickness, guard column (Phenomenex deactivated fused-
silica tubing), splitless injection, injection volume 1L. The GC oven temperature programme starting 
at 35˚C for 8 minutes before ramping at 15˚C/minute and holding at 245˚C for 10 minutes. Total run 
time was 32 minutes with a constant flow of helium at 7.0 mL/minute. Injection temperature 250˚C, 
detector temperature 250˚C. Hydrogen: Air flame (30:300). 
 
2.2.6 Development Testing 
Before validation could be performed it was important to carry out a series of 
verification tests to ensure that no problems would be encountered during full 
validation. These tests were used to ascertain acceptance criteria for system 
suitability that would be required at the start of each validation test. Retention time, 
tailing factor, % RSDs, signal-to-noise values and resolution of the cyclohexanone 
and PGMMEA peaks in the working standard (WS) and detector sensitivity solution 
(DSS) were tracked. The tests included altering a number of the GC conditions 
(robustness) as well as using different systems and different analysts on different 
days (intermediate precision). Mini accuracy and linearity tests were also run using 
spiked product to ensure that all the required levels could achieve acceptable results. 
Expected RT 
of PGMMEA 
 
Expected RT of 
Cyclohexanone 
 
Expected RT 
of PGMEEA 
 
Formulation Peak 
Formulation Peaks 
Formulation Peak 
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The limit of detection and the limit of quantitation were also tested to confirm they 
could be achieved.  
At the end of development all testing had achieved satisfactory results and full 
validation could then commence. 
 
 
2.2.7 System Suitability 
Prior to every test it was required to show that the GC system was capable of 
performing as required. An example of an injection sequence for determining system 
suitability is shown in Table 2.2.  
Note: It was important to ensure that enough blank injections were made such that 
no carryover was observed in two blank injections prior to further injections. 
 
               Table 2.1    Example of System Suitability Injection Sequence 
 
 
 
 
 
The 5 separate injections of WS-1 were used to satisfy the system suitability 
requirements for retention times, tailing factors and peak area % RSD given in Table 
2.2.  
 
Each DSS was injected once. This injection of the DSS was used to satisfy the 
system suitability requirements for DSS signal-to-noise ratio given in Table 2.2. 
 
The analysis could not be carried out if the system suitability criteria listed in Table 
2.2 could not be met. When system suitability criteria could not be met, appropriate 
corrective action had to be taken and the system suitability was repeated. Definitions 
of each term in Table 2.2 can be found in the current USP (United States 
Pharmacopeia 37 2015). 
 
Sample No. of Injections 
Blank Minimum of 2 
LIS 1 
Cyclohexanone DSS 1 
PGMMEA DSS 1 
WS-1 5 
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Table 2.2     System Suitability Criteria 
System Suitability Parameter PGMMEA Cyclohexanone 
Retention Time (WS-1) (n = 5) 12.0 ± 1.0 min  12.5 ± 1.0 min 
Tailing Factor (WS-1) (n = 5) ≤  2.0 ≤  2.0 
% RSD for Peak Area (WS-1) (n = 5) NMT 5% NMT 5% 
Resolution between Cyclohexanone and PGMMEA NLT 5 
DSS Signal-to-Noise (n = 1) NLT 20:1 NLT 10:1 
 
 
2.2.8 Method Validation 
The validation tests that were carried out on the specified leachables cyclohexanone 
and PGMMEA were: accuracy, linearity, range, precision (repeatability and 
intermediate), specificity, standard and sample stability, detection limit (DL), 
quantitation limit (QL) and robustness. As no PGMEEA standard was available, the 
validation tests that were carried out on the specified leachable PGMEEA were: 
precision (repeatability and intermediate), robustness and specificity. For this method 
unknown leachables are estimated using cyclohexanone. Since there was no standard 
material available for PGMEEA and due to its structural similarity to PGMMEA, 
PGMMEA was used to estimate PGMEEA in samples. 
The first test conducted was specificity because if the method was not specific more 
development would have been required. Following on from that the standard and 
sample stability was conducted. This would enable standards to be used over a 
number of days during the rest of validation and thus would save on preparing fresh 
standards every day. Robustness was then carried out followed by the rest of the 
validation tests. 
 
2.2.8.1 Specificity 
To demonstrate the specificity of this method in regards to leachable interferences, 
Product Z laboratory scale preparation was stressed using the following conditions 
and the samples were tested using the method to determine if there are any sample 
interferences at the retention times of cyclohexanone, PGMMEA and PGMEEA. 
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 Adjusted the pH to approximately 2.5 with 5 N HCl and stored at ambient 
temperature in the dark.   
 Adjusted the pH to approximately 11.5 with 5 N NaOH and stored at ambient 
temperature in the dark.   
 Stored at a temperature of 70oC in the dark 
 Added 5 drops of 30% hydrogen peroxide to 60 mL of sample and stored at 
ambient temperature in the dark. 
 Placed in clear glass and stored in an ICH compliant light chamber until ICH 
light stress guidelines (International Conference of Harmonisation 2005) have 
been met. 
The pH adjusted, heat and hydrogen peroxide stressed samples were stored under 
ambient laboratory conditions and pulled at day 14 and then stored at 2 - 8ºC and 
protected from light until time of analysis. The light stressed samples were pulled 
once ICH guidelines had been met. Control samples were untreated and unstressed 
and then stored in the dark at 2 - 8°C. All control samples were from the same batch 
as the treated and stressed samples. 
 
2.2.8.2 Stock Standard Stability 
Stock standard solutions containing cyclohexanone at 1.0% (v/v) and PGMMEA at 
1.0% (v/v) were prepared in amber glassware on day-0. These solutions were 
assayed in triplicate and stored under ambient laboratory temperature and lighting. 
Fresh working standards were prepared for each day of the study from the stock 
standards prepared on day-0. These standards were then re-assayed against freshly 
prepared working standards on day-1, day-3 and day-8 in order to determine the 
chemical stability of the stock standard solutions in amber glassware. A summary of 
the data is presented in Tables 2.4 and 2.5. 
 
2.2.8.3 Intermediate Standard Stability 
Stock standard solutions containing cyclohexanone at 1.0% (v/v) and PGMMEA at 
1.0% (v/v) were prepared in amber glassware. Separate intermediate standard 
solutions containing cyclohexanone and PGMMEA at 0.01% (v/v) were prepared in 
amber glassware from these stock standards and analysed in triplicate on day-0. 
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These solutions were stored under ambient laboratory temperature and lighting and 
re-assayed against freshly prepared working standards on day-1, day-3 and day-8 in 
order to determine the chemical stability of the intermediate standard solutions in 
amber glassware. A summary of the data is presented in Tables 2.6 and 2.7. 
 
2.2.8.4 Working Standard Stability 
Stock standard solutions containing cyclohexanone at 1.0% (v/v) and PGMMEA at 
1.0% (v/v) were prepared in amber glassware. Separate working standard solutions 
containing cyclohexanone and PGMMEA at 0.001% (v/v) were prepared in amber 
glassware from these stock standards and analysed in triplicate on day-0. These 
solutions were stored under ambient laboratory temperature and lighting and re-
assayed against freshly prepared working standards on day-1, day-3 and day-8 in 
order to determine the chemical stability of the working standard solutions in amber 
glassware. A summary of the data is presented in Tables 2.8 and 2.9. 
 
2.2.8.5 Cyclohexanone DSS Stability 
Working standard solutions were freshly prepared in amber glassware. Separate 
cyclohexanone DSS solutions were prepared in amber glassware from these working 
standards and analysed in triplicate on day-0. These solutions were stored under 
ambient laboratory temperature and lighting and re-assayed against freshly prepared 
cyclohexanone DSS on day-1, day-3 and day-8 in order to determine the chemical 
stability of the cyclohexanone DSS solution in amber glassware. A summary of the 
data is presented in Table 2.10. 
 
2.2.8.6 PGMMEA DSS Stability  
Working standard solutions were freshly prepared in amber glassware. Separate 
PGMMEA-DSS solutions were prepared in amber glassware from these working 
standards and analysed in triplicate on day-0. These solutions were stored under 
ambient laboratory temperature and lighting and re-assayed against freshly prepared 
PGMMEA-DSS on day-1, day-3 and day-8 in order to determine the chemical 
stability of the PGMMEA-DSS solution in amber glassware. A summary of the data 
is presented in Table 2.11. 
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2.2.8.7 Leachable Identification Working Solution Stability 
Leachable identification working solution was freshly prepared in amber glassware 
as per section 2.2.4 and analysed in triplicate on day-0. These solutions were stored 
under ambient laboratory temperature and lighting and re-assayed on day-1, day-3 
and day-8 in order to determine the chemical stability of the leachable identification 
working solution in amber glassware.  
 
2.2.8.8 Sample Stability 
Sample solutions of Product Z diluted 1:1 with acetonitrile were freshly prepared in 
amber vials on day-0 as per section 2.2.5.2. These solutions were assayed in triplicate 
and stored under ambient laboratory temperature and lighting. Freshly prepared 
standards were used to reanalyse the test sample preparations after day-1, day-3 and 
day-8.  
 
2.2.8.9 Robustness 
Robustness is the reproducibility of the test results for cyclohexanone, PGMMEA 
and PGMEEA obtained by analysis of Product Z product under deliberate variations 
of the nominal test conditions. Product Z lab scale preparation was spiked with 
Tampoprint thinner solution containing approximately 6.5 ppm cyclohexanone, 6.5 
ppm PGMMEA and 19 ppm PGMEEA. The method ruggedness (robustness) 
validation is demonstrated from the intermediate precision data. Additional 
robustness studies were conducted by analysing the same spiked sample (n = 6) 
using different injector temperatures, detector temperatures, final column 
temperatures and carrier gas flow as shown in Table 2.3.  
Each test condition in Table 2.3 was then evaluated for: 
All System Suitability data:  Report value 
Retention time and relative retention time of PGMEEA 
Mean cyclohexanone, PGMMEA and PGMEEA, ppm data (n = 6) 
Standard deviation of cyclohexanone, PGMMEA and PGMEEA, ppm data (n = 6) 
% RSD of cyclohexanone, PGMMEA, and PGMEEA, ppm data (n = 6) 
Ratio of the means cyclohexanone, PGMMEA and PGMEEA, ppm value versus 
nominal conditions (Test 1) where, X1 = Test 1 and X2 = Test 2 - 9 
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Table 2.3   Robustness Test Conditions 
 Injector 
Temperature 
(ºC) 
Detector 
Temperature 
(ºC) 
Final Oven  
Temperature 
(ºC) 
Carrier Gas 
Flow  
(mL/min) 
Test 1 * 250 250 245 7.0 
Test 2 240 250 245 7.0 
Test 3 260 250 245 7.0 
Test 4 250 240 245 7.0 
Test 5 250 260 245 7.0 
Test 6 250 250 235 7.0 
Test 7 250 250 255 7.0 
Test 8 250 250 245 6.5 
Test 9 250 250 245 7.5 
*Represents nominal analysis conditions of the method 
 
The method robustness tests 1 - 9 given in Table 2.3 were conducted and the resultant 
data is provided in Tables 2.12 to 2.16. The mean cyclohexanone (ppm), PGMMEA 
(ppm) and PGMEEA (ppm) data from robustness test 1 was used to determine the 
ratio of the means results for robustness tests 2 – 9 in Tables 2.14 to 2.16. 
 
2.2.8.10 Accuracy of Cyclohexanone 
Product Z lab scale preparation was spiked with cyclohexanone at approximately 0.5, 
1, 2, 10, 20 and 30 ppm. These levels are equivalent to 2.5%, 5%, 10%, 25%, 50%, 
100% and 150% of cyclohexanone proposed product specification, respectively. This 
was achieved by preparing a cyclohexanone stock solution of 10000 ppm in 
acetonitrile. A 100 ppm spiked solution was then prepared by adding 1 mL of the 
stock to a 100 mL volumetric flask and brought to volume with Product Z lab scale 
formulation. Each spiked preparation was then made by diluting the 100 ppm 
solution in sample. 30 ppm was prepared by adding 3 mL to a 10 mL volumetric 
flask and brought to volume with sample. 20 ppm was prepared by adding 2 mL to a 
10 mL volumetric flask and brought to volume with sample. 10 ppm was prepared by 
adding 1 mL to a 10 mL volumetric flask and brought to volume with sample. 2 ppm 
was prepared by adding 2 mL to a 100 mL volumetric flask and brought to volume 
with sample.  1 ppm was prepared by adding 1 mL to a 100 mL volumetric flask and 
brought to volume with sample. 0.5 ppm was prepared by adding 1 mL to a 200 mL 
volumetric flask and brought to volume with sample. Three separate preparations 
were analysed for the 5%, 10%, 25%, 50% and 150% levels, whereas six separate 
preparations were analysed for the 2.5% and 100% levels.  The ppm concentration of 
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cyclohexanone was calculated for each preparation.  The cyclohexanone accuracy 
results are reported in Table 2.18. 
 
2.2.8.11 Accuracy of PGMMEA 
Product Z lab scale preparation was spiked with PGMMEA at approximately 2, 5, 
10, 20 and 30 ppm PGMMEA. These accuracy levels are equivalent to 10%, 25%, 
50%, 100%, and 150% of PGMMEA proposed product specification, respectively. 
Spiked sample concentrations were prepared in the same manner as 2.2.9.10. Three 
separate preparations were analysed for the 25%, 50% and 150% levels, whereas six 
separate preparations were analysed for the 10% and 100% levels. The ppm 
concentration of PGMMEA was calculated for each preparation. The PGMMEA 
accuracy results are reported in Table 2.19. 
 
2.2.8.12 Cyclohexanone Linearity 
To determine linearity for cyclohexanone, a linearity curve was generated from 0.5 to 
30.0 ppm cyclohexanone.  This range is equivalent to approximately 2.5 to 150% of 
the cyclohexanone proposed product specification.  Each concentration point was run 
in triplicate, except for the 2.5% and 100% target solution which were run 6 times 
(separate preparations). The y-intercept at the origin for peak area data is less than 
5% of the y-intercept at label strength, indicating that a single point calibration can 
be used. This specification is an in-house guideline as regulations require that the y-
intercept only be reported.  Table 2.19 contains the linearity data.  A summary of the 
data can be seen in Table 2.20.  
 
2.2.8.13 PGMMEA Linearity 
To determine linearity for PGMMEA, a linearity curve was generated from 2.0 to 
30.0 ppm PGMMEA.  This range is equivalent to approximately 10% to 150% of the 
PGMMEA proposed product specification.  Each concentration point was run in 
triplicate, except for the 10% and 100% target solution which were run 6 times 
(separate preparations). The y-intercept at the origin for peak area data is less than 
5% of the y-intercept at label strength, indicating that a single point calibration can 
be used. Table 2.21 contains the linearity data.  A summary of the data can be seen in 
Table 2.22.  
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2.2.8.14 Cyclohexanone and PGMMEA Standard Precision (Repeatability) 
Standard precision was determined by injecting 6 replicate injections of 
cyclohexanone and PGMMEA working standard. A summary of the data is shown in 
Table 2.23. 
 
2.2.8.15 Cyclohexanone, PGMMEA and PGMEEA Sample Precision (Repeatability) 
Sample precision was determined by injecting a Tampoprint thinner spiked Product 
Z lab scale preparation containing approximately 6.5 ppm cyclohexanone, 6.5 ppm 
PGMMEA and 19 ppm PGMEEA. A summary of the data is shown in Table 2.24. 
 
2.2.8.16 Cyclohexanone, PGMMEA and PGMEEA Intermediate Precision 
As defined in the glossary, intermediate precision expresses within-laboratories 
variations: different days, different analysts, different equipment. In this case, six 
separate preparations of Product Z, spiked with Tampoprint thinner solution 
containing approximately 6.5 ppm cyclohexanone and PGMMEA and 19 ppm 
PGMEEA were analysed and the amount of cyclohexanone, PGMMEA and 
PGMEEA (ppm) determined by operator-A. On day-2 (operator-A) analysed the 
same spiked sample to provide information concerning day-to-day precision. The 
same instrument and column were used on both days. A summary of the data is 
shown in Tables 2.25 to 2.27. 
A second operator (operator-B) analysed the same spiked product to provide 
information concerning operator-to-operator precision. Operator B used a different 
instrument and different column lot number to operator A. A summary of the data is 
shown in Tables 2.25 to 2.27. 
 
2.2.8.17 Range 
The range is the interval between the lower and upper concentration of analyte in the 
sample for which it has been demonstrated that the analytical procedure has a 
suitable level of precision, accuracy and linearity. The range was established using 
data for accuracy, linearity and precision. 
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2.2.8.18 Detection Limit (DL) Determination for Cyclohexanone and PGMMEA 
The DL of an individual analytical procedure is the lowest amount of analyte in a 
sample which can be detected but not necessarily quantitated as an exact value. 
Typically the DL will be equal to 3 times the standard deviation of the blank. For 
validation purposes the detection limit may often be set at one third of the 
quantitation limit as concentration levels can become so small they are regarded as 
zero. 
The DL of cyclohexanone and the DL of PGMMEA in Product Z were determined 
by preparing a single solution of Product Z lab scale preparation spiked at 0.2 ppm 
with cyclohexanone and 1.0 ppm with PGMMEA. From this solution 3 separate 
preparations were analysed. A summary of the DL data is given in Table 2.28.   
 
2.2.8.19 QL Determination for Cyclohexanone and PGMMEA  
The quantitation limit of an individual analytical procedure is the lowest amount of 
analyte in a sample which can be quantitatively determined with suitable precision 
and accuracy.  
The QL can be specifically calculated using the actual precision of the analytical 
procedure at this concentration. The calculation is based on the compatibility 
between analytical variability and specification acceptance limits. QL can be 
regarded as the maximum true impurity content of the manufactured batch, i.e., as 
the basic limit 
 
 
AL = Acceptance limit of the specification for the impurity. 
s = Precision standard deviation at QL, preferably under intermediate or 
reproducibility conditions. AL and s equal same unit (e.g., percentage weight per 
volume). 
Nassay = Number of repeated, independent determinations in routine analyses, as far 
as the mean is the reportable result, i.e., is compared with the acceptance limits. If 
each individual determination is defined as the reportable result, n=1 has to be used. 
tdf = Student t-factor for the degrees of freedom during determination of the 
precision, usually at 95% level of statistical confidence. 
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The QL of cyclohexanone and the QL of PGMMEA in Product Z were determined by 
preparing a single solution of Product Z lab scale preparation spiked at 0.5 ppm with 
cyclohexanone and 2.0 ppm with PGMMEA. From this solution 6 separate 
preparations were analysed. A summary of the QL data is given in Table 2.29.  
The QL was set at 0.5 ppm and 2.0 ppm for cyclohexanone and PGMMEA 
respectively as these were the predetermined reporting thresholds. It is possible that 
the method could accurately quantitate at lower concentrations but is not necessary 
for the purpose of this method. 
 
 
2.2.9 Sample Analysis 
Injections of the working standard (WS-1) were used for bracketing after every six 
samples.  
 
 
2.3 Results and Discussion 
 
2.3.1 Rationale for Procedure 
This method has been validated for the quantitation of the specified Tampoprint 
leachables cyclohexanone, PGMMEA and PGMEEA. Results from all the validation 
tests are recorded in the following tables (Tables 2.4 to 2.29). 
This method was validated to the current USP Category II (United States 
Pharmacopeia 37 2015) for cyclohexanone, PGMMEA and PGMEEA. The 
validation also complies with ICH Q2 (R1) (International Conference of 
Harmonisation 2005) for assay and impurities. 
 
2.3.2 Specificity  
There were no peaks observed at the retention times of PGMMEA and PGMEEA. 
There was a peak detected at the retention time of cyclohexanone in the samples 
stressed by acid. However, this peak had a signal to noise of considerably less than 
10:1 and therefore meets the acceptance. No significant change in the 
chromatographic profile of the stressed samples was seen when compared with that 
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of the control. The method is deemed to be specific for the determination of 
container closure leachables in Product Z. 
 
2.3.3 Standard Stability 
2.3.3.1 Stock Standard Stability  
Table 2.4     Cyclohexanone Stock Standard Stability – Amber Glassware 
 Day-0 Day-1 Day-3 Day-8 
Mean Cyclohexanone ppm 9.67 9.50 9.00 9.38 
SD ppm 1.3  10-1 7.5  10-2 3.1  10-2 5.0  10-2 
% RSD 1.4 0.7 0.3 0.5 
n 3 3 3 3 
Ratio of the means 
Cyclohexanone ppm values 
(vs. day-0) 
N/A 0.982 0.931 0.970 
 
Table 2.5     PGMMEA Stock Standard Stability – Amber Glassware 
 Day-0 Day-1 Day-3 Day-8 
Mean PGMMEA ppm 9.77 9.89 9.55 9.52 
SD ppm 1.4  10-1 1.5  10-1 5.1  10-2 4.9  10-2 
% RSD 1.4 1.5 0.5 0.5 
n 3 3 3 3 
Ratio of the means PGMMEA 
ppm values (vs. day-0) 
N/A 1.012 0.977 0.974 
 
The acceptance criterion for this study is that the ratio of mean values for 
cyclohexanone and PGMMEA for the stock standard data remains within 0.7 and 1.3 
throughout the testing period. Based on the data, the stock standard is stable for up to 
8 days when stored in amber glassware. 
 
2.3.3.2 Intermediate Standard Stability 
Table 2.6    Cyclohexanone Intermediate Standard Stability – Amber Glassware  
 Day-0 Day-1 Day-3 Day-8 
Mean Cyclohexanone ppm 9.67 9.41 8.82 9.28 
SD ppm 1.3  10-1 1.2  10-1 1.7  10-2 2.3  10-2 
% RSD 1.4 1.3 0.1 0.2 
n 3 3 3 3 
Ratio of the means 
Cyclohexanone ppm values 
(vs. day-0) 
N/A 0.973 0.912 0.959 
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Table 2.7    PGMMEA Intermediate Standard Stability – Amber Glassware 
 Day-0 Day-1 Day-3 Day-8 
Mean PGMMEA ppm 9.77 9.77 9.33 9.48 
SD ppm 1.4  10-1 1.3  10-1 8.3  10-2 7.0  10-2 
% RSD 1.4 1.3 0.8 0.7 
n 3 3 3 3 
Ratio of the means PGMMEA 
ppm values (vs. day-0) 
N/A 1.000 0.954 0.973 
 
The acceptance criterion for this study is that the ratio of mean values for the 
cyclohexanone and the PGMMEA for the intermediate standard data remains within 
0.7 and 1.3 throughout the testing period. Based on the data, the cyclohexanone 
intermediate standard is stable for up to 8 days when stored in amber glassware. 
2.3.3.3 Working Standard Stability 
 
Table 2.8     Cyclohexanone Working Standard Stability – Amber Glassware  
 Day-0 Day-1 Day-3 Day-8 
Mean Cyclohexanone ppm 9.67 9.20 8.78 9.19 
SD ppm 1.3  10-1 1.1  10-1 3.3  10-2 2.4  10-2 
% RSD 1.4 1.2 0.3 0.2 
n 3 3 3 3 
Ratio of the means 
Cyclohexanone ppm values 
(vs. day-0) 
N/A 0.951 0.907 0.950 
 
 
 
Table 2.9     PGMMEA Working Standard Stability – Amber Glassware 
 Day-0 Day-1 Day-3 Day-8 
Mean PGMMEA ppm 9.77 9.50 9.34 9.49 
SD ppm 1.4  10-1 2.3  10-1 2.7  10-2 4.9  10-2 
% RSD 1.4 2.4 0.2 0.5 
n 3 3 3 3 
Ratio of the means PGMMEA 
ppm values (vs. day-0) 
N/A 0.972 0.955 0.971 
 
The acceptance criterion for this study is that the ratio of mean values for the 
cyclohexanone and the PGMMEA for the working standard data remains within 0.7 
and 1.3 throughout the testing period. Based on the data, the cyclohexanone working 
standard is stable for up to 8 days when stored in amber glassware. 
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2.3.3.4 Cyclohexanone DSS Stability 
Table 2.10    Cyclohexanone DSS Stability in Amber Glassware (n = 3) 
Parameter Day-0 Day-1 Day-3 Day-8 
Mean S/N DSS 13.9:1 12.3:1 16.9 20.5 
S/N SD 7.5 × 10-1 1.1 × 100 1.2 × 100 8.9 × 10-1 
S/N % RSD  5.3 9.6 7.5 4.3 
Mean Cyclohexanone peak 
area 
2.56 2.29 2.66 2.65 
SD peak area 1.1 × 10-1 9.1 × 10-2 1.0 × 10-1 2.0 × 10-1 
% RSD  4.4 3.9 3.9 7.8 
Mean % Recovery DSS 101.0 93.8 93.1 102.9 
% Recovery SD 4.4 × 100 3.7 × 100 3.6 × 100 8.0 × 100 
% Recovery % RSD  4.4 3.9 3.9 7.8 
Ratio of the means % 
Recovery values (vs. day-0) 
N/A 0.928 0.921 1.018 
 
The acceptance criterion for this study is that the ratio of mean for the cyclohexanone 
DSS data remains within 0.7 and 1.3 throughout the testing period. Based on the 
data, the cyclohexanone DSS is stable for up to 8 days when stored in amber 
glassware. However, in line with the PGMMEA DSS stability study, the 
cyclohexanone DSS must be prepared fresh on day of analysis. 
 
2.3.3.5 PGMMEA DSS Stability  
Table 2.11    PGMMEA DSS Stability in Amber Glassware (n = 3) 
Parameter Day-0 Day-1 Day-3 Day-8 
Mean S/N DSS 26.1:1 17.5:1 25.4 38.7 
S/N SD 9.5 × 100 1.2 × 100 6.6 × 10-1 1.9 × 100 
S/N % RSD  3.6 7.0 2.6 4.9 
Mean PGMMEA peak area 5.20 3.81 5.24 5.86 
SD peak area 1.4 × 10-1 2.4 × 10-1 3.0 × 10-1 1.4 × 10-1 
% RSD  2.7 6.3 5.7 2.4 
Mean % Recovery DSS 89.9 74.7 86.4 95.6 
% Recovery SD 2.4 × 100 4.8 × 100 5.0 × 100 2.3 × 100 
% Recovery % RSD  2.7 6.4 5.7 2.4 
Ratio of the means % 
Recovery values (vs. day-0) 
N/A 0.830 0.961 1.063 
 
The acceptance criterion for this study is that the ratio of mean for the PGMMEA 
DSS data remains within 0.7 and 1.3 throughout the testing period. However, the 
mean PGMMEA DSS % recovery fails to meet the 80.0 – 120.0% recovery 
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acceptance criterion which is required for system suitability. Based on the data, the 
PGMMEA DSS must be prepared fresh on the day of analysis. 
 
2.3.3.6 Leachable Identification Working Solution Stability 
The acceptance criterion for this study is that there is no significant change in the 
chromatographic profile of the sample solution between day-0 and day-1, day-3 and 
day-8. No deterioration of chromatography or shift in retention time has occurred for 
the cyclohexanone, PGMMEA and PGMEEA peaks throughout the testing period. 
Based on the data, the leachable identification working solution is stable for up to 8 
days when stored in amber glassware. 
 
 
2.3.4 Sample Stability 
The acceptance criterion for this study is that there is no significant change in the 
chromatographic profile of the sample solution between day-0 and day-1 and day-3. 
Chromatography for the sample changed on day-8 testing, with an increase in the 
number of peaks detected, most noticeably at the retention time of the 
cyclohexanone. Based on the data, the sample preparation is stable for up to 3 days 
when stored in amber glassware. 
 
 
2.3.5 Robustness 
Table 2.12   Cyclohexanone Robustness System Suitability Data 
 Retention Time 
Cyclohexanone 
(min) 
Tailing Factor 
Cyclohexanone 
Resolution 
between 
Cyclohexanone 
and PGMMEA 
Signal-to-Noise 
Cyclohexanone 
% RSD 
Cyclohexanone 
Peak Area  
Acceptance 
Criteria 
Report Report Report Report ≤ 5% 
Test 1 * 12.47 1.06 7.6 15.6:1 0.4 
Test 2 12.47 1.07 7.5 15.1:1 0.4 
Test 3 12.47 1.06 7.6 10.7:1 0.4 
Test 4 12.47 1.07 7.6 15.3:1 0.2 
Test 5 12.47 1.08 7.6 14.9:1 0.5 
Test 6 12.46 1.07 7.6 14.0:1 0.2 
Test 7 12.47 1.09 7.6 12.9:1 0.5 
Test 8 12.65 1.08 7.8 12.9:1 0.2 
Test 9 12.29 1.08 7.4 12.3:1 0.4 
*Represents nominal analysis conditions of the method 
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Retention Time (tR) 
The time taken after injection for the analyte molecules to reach the detector. This 
dependent on the column flow rate, column capacity, extra column dead volume and 
the retardation factor of the molecules on the stationary phase. 
 
Tailing Factor  
A measure of how close a chromatographic peak is to a symmetrical shape. As a 
peak slopes the tailing factor increases. 
Tf = ac / 2ab 
where ac is the peak width at 5% of the peak height, and ab is the front half-width 
measured from the leading edge to a perpendicular dropped from the peak apex. 
 
Resolution 
A characteristic of the separation of two adjacent peaks. It may be expressed 
according to the equation: 
RAB = 2 |dR(B) - dR(A)| 
                |w(B) + w(A)| 
where RAB is the resolution, dR(A) and dR(B) are the retention distances (time or 
volume) of each eluted component A and B, and w(A) and w(B) are the respective 
widths of each peak at its base. 
 
Table 2.13   PGMMEA Robustness System Suitability Data 
 Retention Time 
PGMMEA 
(min) 
Tailing Factor 
PGMMEA 
% RSD 
PGMMEA Peak 
Area 
Signal-to-Noise 
PGMMEA 
Acceptance  
Criteria 
Report Report ≤ 5% Report 
Test 1 * 12.05 1.26 0.4 29.0:1 
Test 2 12.05 1.25 0.6 30.1:1 
Test 3 12.05 1.22 0.4 24.5:1 
Test 4 12.05 1.23 0.6 32.2:1 
Test 5 12.05 1.24 0.6 28.2:1 
Test 6 12.05 1.22 0.4 30.6:1 
Test 7 12.05 1.25 0.4 27.2:1 
Test 8 12.23 1.24 0.2 25.1:1 
Test 9 11.88 1.24 0.3 23.5:1 
  *Represents nominal analysis conditions of the method 
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 Table 2.14   Cyclohexanone Robustness Data 
 Mean 
Cyclohexanone 
(ppm) 
SD  
Cyclohexanone 
(ppm) 
% RSD 
Cyclohexanone 
(ppm) 
Ratio of the 
Means 
Cyclohexanone 
Acceptance 
Criteria 
Report Report ≤ 5% 0.7 – 1.3 
Test 1 * 7.06 1.1 × 10-1 1.6 N/A 
Test 2 7.52 1.8 × 10-1 2.4 1.1 
Test 3 6.95 1.4 × 10-1 2.1 1.0 
Test 4 7.10 1.2 × 10-1 1.6 1.0 
Test 5 7.11 1.1 × 10-1 1.6 1.0 
Test 6 6.98 1.5 × 10-1 2.2 1.0 
Test 7 6.93 1.4 × 10-1 2.0 1.0 
Test 8 6.72 8.6 × 10-2 1.2 1.0 
Test 9 7.18 8.3 × 10-2 1.1 1.0 
*Represents nominal analysis conditions of the method 
           
 
 Table 2.15   PGMMEA Robustness Data 
 Mean PGMMEA 
(ppm) 
SD PGMMEA 
(ppm) 
% RSD 
PGMMEA 
(ppm) 
Ratio of the 
Means 
PGMMEA 
Acceptance  
Criteria 
Report Report ≤ 5% 0.7 – 1.3 
Test 1 * 6.14 7.6 × 10-2 1.2 N/A 
Test 2 6.55 1.0 × 10-1 1.5 1.1 
Test 3 6.12 1.4 × 10-1 2.3 1.0 
Test 4 6.25 1.3 × 10-1 2.1 1.0 
Test 5 6.29 1.6 × 10-1 2.5 1.0 
Test 6 6.13 1.4 × 10-1 2.4 1.0 
Test 7 6.21 1.8 × 10-1 2.9 1.0 
Test 8 6.24 9.0 × 10-2 1.4 1.0 
Test 9 6.46 8.3 × 10-2 1.2 1.1 
*Represents nominal analysis conditions of the method 
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 Table 2.16   PGMEEA Robustness Data 
 Retention 
Time 
PGMEEA 
(min) 
Relative 
Retention 
Time 
PGMEEA 
Mean 
PGMEEA 
(ppm) 
SD 
PGMEEA 
(ppm) 
% RSD 
PGMEEA 
(ppm) 
Ratio of 
the Means 
PGMEEA 
Acceptance 
Criteria 
Report Report Report Report ≤ 5% 0.7 – 1.3 
Test 1 * 13.07 1.04 19.12 2.8 × 10-1 1.4 N/A 
Test 2 13.07 1.04 20.57 5.2 × 10-1 2.5 1.1 
Test 3 13.07 1.04 18.96 4.0 × 10-1 2.1 1.0 
Test 4 13.07 1.04 19.64 2.9 × 10-1 1.5 1.0 
Test 5 13.07 1.04 19.76 3.4 × 10-1 1.7 1.0 
Test 6 13.07 1.04 19.30 4.0 × 10-1 2.0 1.0 
Test 7 13.07 1.04 19.50 4.1 × 10-1 2.1 1.0 
Test 8 13.23 1.04 19.12 1.8 × 10-1 0.9 1.0 
Test 9 12.91 1.05 20.34 2.3 × 10-1 1.1 1.1 
*Represents nominal analysis conditions of the method 
 
Conclusion of Robustness Study 
The data indicates that all System Suitability criteria were met for all challenges. The 
method is capable of withstanding: 
 ± 10°C variation in injector temperature  
 ± 10°C variation in detector temperature  
 ± 10°C variation in final oven temperature  
 ± 0.5 mL/min change in carrier gas flow 
 
Overall, the method is considered robust and suitable for routine use where accurate 
and reliable quantitative data is required for cyclohexanone, PGMMEA, PGMEEA 
and other potential leachables.  
The information derived from the precision section provides an additional measure of 
method ruggedness. Using different analysts, on different days and different columns 
will yield chromatography and quantitative cyclohexanone, PGMMEA and 
PGMEEA values that are very consistent. This demonstrates that the method is 
sufficiently rugged, reproducible and robust under conditions of routine laboratory 
usage. 
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2.3.6  Accuracy  
2.3.6.1 Product Z Placebo Interferences  
Three replicate injections of Product Z lab scale preparation showed no interferences 
with a S/N ratio greater than 10:1 at the location of the cyclohexanone, PGMMEA 
and PGMEEA peaks.  This lack of placebo (i.e. lab-scale product made as per the 
manufacturing procedure but with the omission of at least one active ingredient 
contained within the full formulation)  interference meets the acceptance criteria.  
 
2.3.6.2 Accuracy Data for Cyclohexanone 
Table 2.17  Accuracy Data for Cyclohexanone 
Conc. ppm 0.5 1 2 5 10 20 30 
Conc. ppm 0.48 
0.47 
0.50 
0.47 
0.49 
0.47 
0.97 
0.98 
0.94 
 
1.76 
1.78 
1.77 
3.94 
4.32 
4.30 
8.53 
8.57 
8.28 
17.30 
17.45 
17.26 
16.44 
15.89 
16.47 
26.78 
26.32 
24.98 
Mean Conc. ppm 0.49 0.97 1.78 4.19 8.46 16.81 26.03 
SD, Conc. ppm 1.2 × 10
-2
 1.8 × 10
-2
 1.2 × 10
-2
 2.1 × 10
-1
 1.5 × 10
-1
 6.2 × 10
-1
 9.3 × 10
-1
 
% RSD, Conc. ppm 2.6 1.9 0.7 5.0 1.8 3.7 3.5 
% Recovery 102.74 
100.42 
107.18 
101.05 
104.22 
100.00 
103.06 
103.69 
100.00 
93.13 
94.45 
93.66 
83.29 
91.23 
90.93 
90.09 
90.51 
87.46 
91.37 
92.15 
91.15 
86.83 
83.92 
86.97 
94.26 
92.67 
87.93 
Mean % Recovery 102.6 102.3 93.7 88.5 89.4 88.7 91.6 
SD, % Recovery 2.7 × 10
0
 1.9 × 10
0
 6.6 × 10
-1
 4.5 × 10
0
 1.6 × 10
0
 3.2 × 10
0
 3.2 × 10
0
 
% RSD, % Recovery 2.6 1.9 0.7 5.0 1.8 3.7 3.5 
n  6 3 3 3 3 6 3 
 
The mean accuracy values obtained meets the acceptance criteria of 80.0% - 
120.0%.  The individual accuracy requirement of 70.0% - 130.0% was also met 
for each individual preparation.   
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2.3.6.3 Accuracy Data for PGMMEA 
Table 2.18       Accuracy Data for PGMMEA 
Conc. ppm 2 5 10 20 30 
Conc. ppm 1.93 
1.90 
1.91 
1.94 
1.88 
1.70 
4.15 
4.52 
4.46 
 
8.77 
8.79 
8.49 
17.61 
17.66 
17.48 
16.77 
16.18 
16.75 
27.32 
26.91 
25.45 
Mean Conc. ppm 1.88 4.38 8.69 17.08 26.56 
SD, Conc. ppm 8.8 × 10
-2
 1.9 × 10
-1
 1.6 × 10
-1
 6.0 × 10
-1
 9.8 × 10
-1
 
% RSD, Conc. ppm  4.7 4.5 1.9 3.5 3.6 
% Recovery 99.58 
98.35 
98.50 
100.46 
97.26 
87.93 
85.64 
93.23 
92.02 
90.41 
90.65 
87.55 
90.81 
91.07 
90.11 
86.48 
83.40 
86.38 
93.88 
92.48 
87.47 
Mean % Recovery 97.0 90.3 89.5 88.0 91.3 
SD, % Recovery 4.5 × 10
0
 4.0 × 10
0
 1.7 × 10
0
 3.0 × 10
0
 3.3 × 10
0
 
% RSD, % Recovery 4.7 4.5 1.9 3.5 3.6 
n  6 3 3 6 3 
 
The mean accuracy values obtained meets the acceptance criteria of 80.0% - 
120.0%.  The individual accuracy requirement of 70.0% - 130.0% was also met 
for each individual preparation.   
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2.3.7 Linearity 
2.3.7.1 Cyclohexanone Linearity  
 
Table 2.19     Cyclohexanone Linearity Concentrations and Peak Areas 
Concentration (ppm) Peak Area % Specification Limit  
0.5 2.594 2.5 
0.5 2.700 2.5 
0.5 2.621 2.5 
0.5 2.780 2.5 
0.5 2.605 2.5 
0.5 2.665 2.5 
1.0 5.268 5 
1.0 5.459 5 
1.0 5.427 5 
2.0 9.709 10 
2.0 9.791 10 
2.0 9.651 10 
5.0 23.717 25 
5.0 23.793 25 
5.0 21.721 25 
10.0 45.632 50 
10.0 47.222 50 
10.0 47.002 50 
20.0 90.731 100 
20.0 87.541 100 
20.0 90.576 100 
20.0 95.114 100 
20.0 96.159 100 
20.0 95.345 100 
30.0 137.593 150 
30.0 145.009 150 
30.0 147.494 150 
 
 
Table 2.20     Linearity for Cyclohexanone Data Summary  
Parameter Values 
Correlation Coefficient, r 0.998 
Y-intercept, Y0 -0.028 
Y at label strength, Y100 92.6 
% Y0/Y100 = (Y0/Y100) x 100% 0.03 
Slope, m 4.97 
Regression Equation y = 4.97(x) + (-0.028) 
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Linearity requirements for cyclohexanone have been established and meet the 
acceptance criteria of not more than (NMT) 2% for y intercept. See Figure 2.4 for the 
cyclohexanone linearity curve (Label Strength = 20 ppm). 
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Figure 2.4: Linearity Plot of Cyclohexanone from 0.5 – 30.0 ppm, Equivalent to  
                   2.5 – 150% of Cyclohexanone Product Specification 
 
The graph in Figure 2.4 shows a best fit line for the average of each set of replicates. 
There are 6 replicates for the 0.5 and 20 ppm concentrations and 3 replicates for the 
rest. 
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2.3.7.2 PGMMEA Linearity  
Table 2.21      PGMMEA Linearity Concentrations and Peak Areas 
Concentration (ppm) Peak Area % Specification Limit  
2.0 5.423 10 
2.0 5.998 10 
2.0 6.196 10 
2.0 6.041 10 
2.0 6.030 10 
2.0 6.107 10 
5.0 14.186 25 
5.0 14.374 25 
5.0 13.203 25 
10.0 26.990 50 
10.0 27.948 50 
10.0 27.870 50 
20.0 53.195 100 
20.0 51.362 100 
20.0 53.260 100 
20.0 55.561 100 
20.0 56.149 100 
20.0 55.988 100 
30.0 80.803 150 
30.0 85.432 150 
30.0 86.723 150 
 
 
Table 2.22  Linearity for PGMMEA Data Summary 
Parameter Values 
Correlation Coefficient, r 0.998 
Y-intercept, Y0 0.056 
Y at label strength, Y100 54.3 
% Y0/Y100 = (Y0/Y100) x 100% 0.10 
Slope, m 2.85 
Regression Equation y = 2.85(x) + 0.056 
 
Linearity requirements for PGMMEA have been established and meet the acceptance 
criteria of NMT 2% for y intercept. See Figure 2.5 for the PGMMEA linearity curve. 
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Linearity Plot of PGMMEA Concentration (ppm) versus PGMMEA Peak Area
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Figure 2.5: Linearity Plot of PGMMEA from 2.0 – 30.0 ppm, Equivalent to  
                   10 – 150% of PGMMEA Product Specification  
 
 
Similar to Figure 2.4, the graph in Figure 2.5 shows a best fit line for the average of  
each set  of replicates. There are 6 replicates for the 2 and 20 ppm concentrations and  
3 replicates for the remaining concentrations. 
 
 
 
 
 
 
 
 
 
 
       Linearity Plot of PGMMEA Peak Area versus PGMMEA Concentration (ppm) 
      PG MEA Concen ration (ppm) 
  
  
  
  
P
G
M
M
E
A
 P
ea
k
 A
re
a 
62 
 
2.3.8 Precision (Repeatability and Intermediate Precision) 
2.3.8.1 Cyclohexanone and PGMMEA Standard Precision (Repeatability) 
Table 2.23     Cyclohexanone and PGMMEA Standard Precision Data 
 
The % RSD meets the acceptance criterion of ≤ 5%. 
 
 
2.3.8.2 Cyclohexanone, PGMMEA and PGMEEA Sample Precision (Repeatability) 
Table 2.24      Cyclohexanone, PGMMEA and PGMEEA Sample Precision Data 
 
The % RSD meets the acceptance criterion of ≤ 5%. 
 
 
2.3.8.3 Cyclohexanone, PGMMEA and PGMEEA Operator-A Day-1/Day-2 
(Intermediate Precision) 
Table 2.25    Cyclohexanone Day-to-Day Intermediate Precision Data 
Parameter Operator-A 
Day-1 
Operator-A 
Day-2 
Operator-B 
 
Mean ppm 7.06 6.68 7.74 
SD ppm 1.1 × 10-1 2.3 × 10-2 3.5 × 10-1 
% RSD  1.6 0.3 4.5 
Confidence interval 7.06 ± 0.11 6.68 ± 0.02 7.74 ± 0.36 
n 6 6 6 
Ratio of the means,  
operator-A day-2/day-1 
0.9 
Ratio of the means,  
operator-B/operator-A day-1 
1.1 
 
Parameter Cyclohexanone Results PGMMEA Results 
Mean Peak Area 102.99 60.95 
SD Peak Area 4.6 × 10-1 2.3 × 10-1 
% RSD  0.4 0.3 
Confidence interval 102.99 ± 0.48 60.95 ± 0.24 
n 6 6 
Parameter Cyclohexanone 
Results 
PGMMEA Results PGMEEA Results 
Mean ppm 7.06 6.14 19.12 
SD ppm 1.1 × 10-1 7.6 × 10-2 2.8 × 10-1 
% RSD  1.6 1.2 1.4 
Confidence interval 7.06 ± 0.11 6.14 ± 0.07 19.12 ± 0.29 
n 6 6 6 
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Table 2.26     PGMMEA Day-to-Day Intermediate Precision Data 
Parameter Operator-A 
Day-1 
Operator-A 
Day-2 
Operator-B 
 
Mean ppm 6.14 6.31 6.57 
SD ppm 7.6 × 10-2 5.3 × 10-2 2.5 × 10-1 
% RSD  1.2 0.8 3.9 
Confidence interval 6.14 ± 0.07 6.31 ± 0.05 6.57 ± 0.26 
n 6 6 6 
Ratio of the means,  
operator-A day-2/day-1 
1.0 
Ratio of the means,  
operator-B/operator-A day-1 
1.1 
 
 
 
Table 2.27    PGMEEA Day-to-Day Intermediate Precision Data 
Parameter Operator-A 
Day-1 
Operator-A 
Day-2 
Operator-B 
 
Mean ppm 19.12 19.80 22.68 
SD ppm 2.8 × 10-1 9.7 × 10-2 1.0 × 100 
% RSD  1.4 0.4 4.6 
Confidence interval 19.12 ± 0.29 19.80 ± 0.10 22.68 ± 1.00 
n 6 6 6 
Ratio of the means,  
operator-A day-2/day-1 
1.0 
Ratio of the means,  
operator-B/operator-A day-1 
1.2 
 
The ratio of the means value (ppm) for cyclohexanone, PGMMEA and PGMEEA 
meets the acceptance criterion of between 0.7 and 1.3 for cyclohexanone, PGMMEA 
and PGMEEA intermediate precision.  The % RSD values meet the acceptance 
criterion of % RSD ≤ 5.0 for n = 6. 
 
2.3.9 Range 
The range for cyclohexanone has been established from 0.5 ppm to 30.0 ppm which 
corresponds to 2.5 to 150% of the proposed product specification. The range for 
PGMMEA has been established from 2.0 ppm to 30.0 ppm which corresponds to 10 
to 150% of the working standard concentration. This was achieved through 
measurements for accuracy, linearity and precision. 
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2.3.10 Detection Limit (DL) 
DL Determination for Cyclohexanone and PGMMEA 
Table 2.28    DL of Cyclohexanone and PGMMEA in Product Z 
Parameter Cyclohexanone Results PGMMEA Results 
Mean ppm 0.21 0.86 
Mean S/N Ratio 4.9:1 9.3:1 
% RSD of Peak Height 3.9 2.1 
n 3 3 
 
Based upon the data shown in Table 2.28, the DL for cyclohexanone is determined to 
be 0.2 ppm and the DL for PGMMEA is determined to be 0.9 ppm.  
 
2.3.11 Quantitation Limit (QL) 
QL Determination for Cyclohexanone and PGMMEA  
Table 2.29    QL of Cyclohexanone and PGMMEA in Product Z 
Parameter Cyclohexanone Results PGMMEA Results 
Mean ppm 0.49 1.88 
Mean % Recovery 102.6 97.0 
Mean S/N Ratio 11.3:1 23.9:1 
% RSD of Peak Height 2.9 4.3 
n 6 6 
 
Based upon the data shown in Table 2.29, the QL for cyclohexanone is determined to 
be 0.5 ppm and the QL for PGMMEA is determined to be 1.9 ppm.   
Mean % recovery of both cyclohexanone and PGMMEA also meets the acceptance 
criteria of 100.0% ± 20.0%. 
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2.4 Conclusion 
 
The concentration of container closure leachables are determined by diluting the 
samples 1:1 with acetonitrile and injecting onto the gas chromatographic DB-5 
capillary column. Volatile and semi-volatile organic compounds are detected using a 
flame ionisation detector (FID). A temperature program is incorporated which allows 
the separation of potential volatile compounds from higher boiling compounds. The 
ability of the FID to detect virtually any volatile or semi-volatile organic compound 
with a carbon-hydrogen bond makes it ideal for this ‘finger printing’ comparison test 
which will detect a wide variety of potential organic leachables and is sensitive down 
to less than 1 ppm for common organic solvents. Cyclohexanone is quantitated and 
unknown leachables are estimated against cyclohexanone in the standard; PGMMEA 
is quantitated and PGMEEA is estimated against PGMMEA in the standard. 
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Chapter 3: Validation of a Headspace Gas Chromatography Method for the 
Analysis of Tampoprinting Leachates 
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3.1 Introduction 
 
This method uses headspace gas chromatography to detect and quantitate the 
concentrations of the Tampoprint-related leachables cyclohexanone and propylene 
glycol monoethyl ether acetate (PGMEEA), and estimate propylene glycol 
monomethyl ether acetate (PGMMEA). It also estimates the concentration of other 
potential volatile and semi-volatile container closure leachable components by 
comparison of gas chromatographic (GC) profiles of ophthalmic solution samples 
stored in plastic container/closure systems versus identical samples stored in glass (or 
unlabelled plastic containers) as a control. Comparison of these two chromatographic 
‘finger prints’ forms the basis of evaluating the presence of volatile and semi-volatile 
leachables. If gas chromatographic profiles are the same for test and control samples, 
it is strong evidence that no such leachables are present in the ophthalmic solution. 
The Tampoprint-related leachables that are seen in Product X have not previously 
been tested for this product and thus a new method is required. 
This method will be validated in accordance with the current USP Category II 
(United States Pharmacopeia 37 2015) for cyclohexanone, PGMMEA and PGMEEA. 
The validation will also meet all requirements under ICH guidelines Q2 (R1) 
(International Conference of Harmonisation 2005). 
The proposed method validation tests that will be carried out on the specified 
leachables cyclohexanone and PGMMEA are: accuracy, linearity, range, precision 
(repeatability and intermediate), specificity, detection limit (DL), quantitation limit 
(QL), robustness and standard stability. As no PGMEEA standard is available, the 
validation tests that will be carried out on the specified leachable PGMEEA are: 
precision (repeatability and intermediate), robustness and specificity. Since there is 
no standard material available for PGMEEA and due to its structural similarity 
PGMMEA will be used to estimate PGMEEA in samples. 
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3.2 Experimental 
 
3.2.1 Initial Development 
After developing and validating the method for Product Z, the same method was 
trialled on Product X. However, the sample matrix was quite different and resulted in 
a lot of interference with the cyclohexanone and PGMMEA peaks. Accuracy results 
were also poor and it was decided to move away from the direct injection GC method 
and try a headspace (HS) GC method instead.  
As the external toxicological assessment had previously found that each of the 
leachables were safe up to a limit of 20 ppm, standards were required to be prepared 
at a final working concentration of 20 ppm.  
A particular headspace GC method that was used in the laboratory to test different 
leachables was trialled using cyclohexanone and PGMMEA standards. The GC 
conditions employed were an oven temperature programme starting at 35˚C for 8 
minutes before ramping at 15˚C/minute and holding at 245˚C for 10 minutes. Total 
run time was 32 minutes with a constant flow of helium at 5.0 mL/minute. The inlet 
was set at 250˚C with a split ratio of 1.0. The detector was set at 250˚C and the 
makeup gas was helium at 20 mL/minute. Hydrogen was used for the fuel flow at 45 
mL/minute and air was used for the oxidiser flow at 450 mL/minute. The headspace 
sampler utilised a vial oven temperature of 80˚C, a loop temperature of 130˚C and a 
transfer line temperature of 140˚C. Agitation was set to high and vial pressurisation 
at 16 psi. Oven stabilisation was set at 1 minute, vial equilibration at 20 minutes, vial 
pressurisation at 0.4 minutes, loop fill at 0.2 minutes, loop equilibration at 0.2 
minutes and sample inject at 0.5 minutes. 
The baseline was a lot better with much less interference but peak shape was poor. 
The method utilised an Agilent DB-WAX column so it was changed for the DB5 
column as that had previously shown good chromatography for the cyclohexanone 
and PGMMEA. The results were much improved with good peak shape and 
resolution so it was decided to proceed with the DB5 column.  
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3.2.2 Reagents 
Analytical grade cyclohexanone and propylene glycol monomethyl ether acetate 
(PGMMEA) were purchased from Sigma Aldrich (Poole, UK). Tampoprint thinner, 
VDL-1015 was purchased from Tampoprint (Stuttgart, Germany).  
Solvents used included acetonitrile (HPLC grade) which was purchased from 
Labscan (Dublin, Ireland) and dimethylacetamide purchased from VWR 
(Pennsylvania, USA). Ultrapure water was obtained from a Millipore Milli-Q water 
purification unit (Millipore, Bedford, MA, USA).  High purity grade compressed air, 
hydrogen and helium were purchased from BOC (Surrey, UK).  
 
3.2.3 Instrumentation and Apparatus 
An Agilent 7890 GC system with FID, Agilent G1888 headspace sampler and 
Agilent DB-5 column, 30 m x 0.53 mm x 1.0 µm film thickness (part number 125-
503J) were utilised for all testing. A deactivated fused silica tubing guard column 
(Phenomenex, part number 7CK-G000-00-GZK) was attached to the column. 
Graphite ferrules by Agilent were used to attach the column to the GC system (part 
number 5080-8773). 10 mL amber headspace screw top vials were from Agilent (part 
number 5188-6538). An Agilent glass liner was used for split operation, 4 mm, non-
deactivated borosilicate glass (part number 19251-60540). The injector septa and    
o-ring were also from Agilent (part number 5183-4757 and 5188-5365 respectively). 
The GC utilised an oven temperature programme starting at 35˚C for 8 minutes 
before ramping at 15˚C/minute and holding at 245˚C for 10 minutes. Total run time 
was 32 minutes with a constant flow of helium at 5.0 mL/minute. The inlet was set at 
250˚C with a split ratio of 1.0. The detector was set at 250˚C and the makeup gas was 
helium at 20 mL/minute. Hydrogen was used for the fuel flow at 45 mL/minute and 
air was used for the oxidiser flow at 450 mL/minute. The headspace sampler utilised 
a vial oven temperature of 80˚C, a loop temperature of 130˚C and a transfer line 
temperature of 140˚C. Agitation was set to high and vial pressurisation at 16 psi. 
Oven stabilisation was set at 1 minute, vial equilibration at 20 minutes, vial 
pressurisation at 0.4 minutes, loop fill at 0.2 minutes, loop equilibration at 0.2 
minutes and sample inject at 0.5 minutes. 
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Glassware was provided by Schott (Mainz, Germany) and consisted of 0.5 mL, 1 
mL, 2 mL, 3 mL, and 4 mL volumetric pipettes (Class A) as well as 20 mL amber 
volumetric flasks (Class A). All glassware was washed in a Hamo LS2000 glass 
washer using RBS 50 pF detergent and RBS R 60 acid. Both the detergent and acid 
were purchased from Chemical Products R. Borghgraef S.A. (Brussels, Belgium). 
A calibrated micro syringe capable of dispensing 6 µL was purchased from Agilent 
(part number 5181-3354). 
 
3.2.4 Standard Preparation 
A stock standard (SS) was prepared by pipetting 1 mL of cyclohexanone and 1 mL of 
PGMMEA into a 20 mL amber volumetric flask containing 4 mL of 
dimethylacetamide (as solvent). The flask was gently swirled and then brought to 
volume with deionised water and mixed using a magnetic stirrer for 15 minutes.  
An intermediate standard was prepared by pipetting 4 mL of the stock standard 
solution into a 20 mL amber volumetric flask, containing approximately 10 mL of 
deionised water. The volumetric flask was brought to volume with deionised water 
and mixed using a magnetic stirrer for 15 minutes.  
Working standards were prepared by transferring a portion of the intermediate 
standard solution into a 4 mL amber HPLC vial and capping. 3 mL of Product X was 
then pipetted into the headspace vial. Using a calibrated micro syringe, the septum of 
the HPLC vial was pierced and 6 µL of the intermediate standard solution removed 
and dispensed into the headspace vial containing 3 mL of Product X before capping 
immediately. The nominal concentration of the working standard solution was 18.94 
ppm for cyclohexanone and 19.4 ppm for PGMMEA. A typical chromatogram of the 
working standard solution can be seen in Figure 3.1. Working standard 
concentrations are based on the cyclohexanone density of   0.947 g/mL and the 
PGMMEA density of 0.970 g/mL. 
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Figure 3.1: GC-FID of WS (cyclohexanone 18.94 ppm; PGMMEA 19.40 ppm). GC Conditions: 
Agilent 7890 GC FID, Agilent G1888 headspace sampler, Agilent Capillary DB-5 column, 30 m x 
0.53 mm x 1.0 µm film thickness, guard column (Phenomenex deactivated fused-silica tubing), split 
injection with split ratio of 1.0, injection volume 1000L. The GC oven temperature programme 
starting at 35˚C for 8 minutes before ramping at 15˚C/minute and holding at 245˚C for 10 minutes. 
Total run time was 32 minutes with a constant flow of helium at 5.0 mL/minute. Injection temperature 
250˚C, detector temperature 250˚C. Hydrogen: Air flame (45:450). Vial oven temperature 80˚C, loop 
temperature 130˚C, transfer line temperature 140˚C. High agitation, vial pressurisation 16 psi, oven 
stabilisation 1 minute, vial equilibration 20 minutes, vial pressurisation 0.4 minutes, loop fill 0.2 
minutes, loop equilibration 0.2 minutes, sample inject 0.5 minutes. 
 
A PGMMEA intermediate detector sensitivity solution (I-DSS) was prepared by 
transferring 2 mL of the intermediate standard solution into a 20 mL amber 
volumetric flask containing approximately 10 mL of deionised water and diluting to 
volume with deionised water. It was mixed using a magnetic stirrer for 15 minutes.  
The PGMMEA detector sensitivity solution (DSS) was then prepared by transferring 
a portion of the PGMMEA intermediate detector sensitivity solution into a 4 mL 
amber HPLC vial and capping. 3 mL of Product X was then pipetted into a 
headspace vial. Using a calibrated micro syringe, the septum of the HPLC vial was 
pierced and 6 µL of the intermediate detector sensitivity solution removed and 
dispensed into the headspace vial containing 3 mL of Product X before capping 
immediately. The nominal PGMMEA concentration of the working DSS was 1.94 
ppm.  
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A cyclohexanone intermediate detector sensitivity solution was prepared in a similar 
manner to the PGMMEA I-DSS using 0.5 mL of the intermediate standard solution 
rather than 2 mL.  
A cyclohexanone detector sensitivity solution was prepared in the same way as the 
PGMMEA DSS. The nominal cyclohexanone concentration of the working DSS was 
0.473 ppm. 
A Tampoprint thinner stock solution was prepared by transferring 4 mL of 
dimethylacetamide into a 20 mL amber volumetric flask. 1 mL of the Tampoprint 
thinner solution was then pipetted into the same 20 mL amber volumetric flask. The 
flask was gently swirled and brought to volume with deionised water before mixing 
using a magnetic stirrer for 15 minutes.  
A leachable identification stock solution (S-ID) was then prepared by transferring 4 
mL of the tampoprint thinner stock solution into a 20 mL amber volumetric flask, 
containing approximately 10 mL of deionised water. The volumetric flask was 
brought to volume with deionised water and mixed using a magnetic stirrer for 15 
minutes.  
A leachable identification working solution (LIS) was then prepared by transferring a 
portion of the S-ID into a 4 mL amber HPLC vial and capping. 3 mL of Product X 
was then pipetted into a headspace vial. Using a calibrated micro syringe, the septum 
of the HPLC vial was pierced and 6 µL of the S-ID removed and dispensed into the 
headspace vial containing 3 mL of Product X before capping immediately. A typical 
chromatogram of the LIS can be seen in Figure 3.2.  
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Figure 3.2: GC-FID of LIS. GC Conditions: Agilent 7890 GC FID, Agilent G1888 headspace 
sampler, Agilent Capillary DB-5 column, 30 m x 0.53 mm x 1.0 µm film thickness, guard column 
(Phenomenex deactivated fused-silica tubing), split injection with split ratio of 1.0, injection volume 
1000L. The GC oven temperature programme starting at 35˚C for 8 minutes before ramping at 
15˚C/minute and holding at 245˚C for 10 minutes. Total run time was 32 minutes with a constant flow 
of helium at 5.0 mL/minute. Injection temperature 250˚C, detector temperature 250˚C. Hydrogen: Air 
flame (45:450). Vial oven temperature 80˚C, loop temperature 130˚C, transfer line temperature 
140˚C. High agitation, vial pressurisation 16 psi, oven stabilisation 1 minute, vial equilibration 20 
minutes, vial pressurisation 0.4 minutes, loop fill 0.2 minutes, loop equilibration 0.2 minutes, sample 
inject 0.5 minutes. 
 
Calibration controls were prepared by transferring 3 mL of Product X into a 
headspace vial and capping immediately. These controls were run due to the 
possibility of the presence of interference at the retention time of cyclohexanone or 
PGMMEA due to the sensitivity of the method. As standards are added to the sample 
the control allows for any standard peaks seen in the un-spiked sample to be 
calculated and taken away from the standard amount to give an accurate value.  
 
Blanks (to capture possible laboratory contaminants) were prepared by capping 
empty headspace vials and were used to identify any system related peaks unrelated 
to the sample.  
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3.2.5 Sample Preparation 
3.2.5.1 Product X Control Samples 
Product X control samples are Product X samples stored in glass containers, glass 
ampoules, unlabelled bottles or bottles with blank labels depending on the nature of 
the leachable study. Product X control sample was pooled into a glass container from 
a number of glass ampoules before pipetting 3 mL of Product X control sample into 
headspace vials and capping immediately.  
3.2.5.2 Product X Test Sample 
Product X test sample was prepared in the same manner as the control sample by 
pooling sample from final product plastic bottles (with Tampoprint labelling) into a 
glass container.   3 mL of Product X sample was then pipetted into headspace vials 
and capped immediately. See Figure 3.3 for a typical chromatogram of a Product X 
control sample.  
 
Figure 3.3: GC-FID of Product X Control. GC Conditions: Agilent 7890 GC FID, Agilent G1888 
headspace sampler, Agilent Capillary DB-5 column, 30 m x 0.53 mm x 1.0 µm film thickness, guard 
column (Phenomenex deactivated fused-silica tubing), split injection with split ratio of 1.0, injection 
volume 1000L. The GC oven temperature programme starting at 35˚C for 8 minutes before ramping 
at 15˚C/minute and holding at 245˚C for 10 minutes. Total run time was 32 minutes with a constant 
flow of helium at 5.0 mL/minute. Injection temperature 250˚C, detector temperature 250˚C. 
Hydrogen: Air flame (45:450). Vial oven temperature 80˚C, loop temperature 130˚C, transfer line 
temperature 140˚C. High agitation, vial pressurisation 16 psi, oven stabilisation 1 minute, vial 
equilibration 20 minutes, vial pressurisation 0.4 minutes, loop fill 0.2 minutes, loop equilibration 0.2 
minutes, sample inject 0.5 minutes. 
Expected RT 
of PGMMEA 
 Expected RT of 
Cyclohexanone 
Expected RT 
of PGMEEA 
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3.2.6 Development Testing 
Before validation could be performed it was important to carry out a series of 
verification tests to ensure that no problems would be encountered during full 
validation. These tests were used to ascertain acceptance criteria for system 
suitability that would be required at the start of each validation test. Retention time, 
tailing factor, % RSDs, signal-to-noise values and resolution of the cyclohexanone 
and PGMMEA peaks in the working standard and DSS were tracked. The tests 
included altering a number of the GC conditions (robustness) as well as using 
different systems and different analysts on different days (intermediate precision). 
Mini accuracy and linearity tests were also run using spiked product to ensure that all 
the required levels could achieve acceptable results. The limit of detection and the 
limit of quantitation were also tested to confirm they could be achieved.  
At the end of development all testing had achieved satisfactory results and full 
validation could then commence. 
 
 
3.2.7 System Suitability 
Prior to every test it was required to show that the GC system was capable of 
performing as required. An example of an injection sequence for determining system 
suitability is shown in Table 3.1.  
Note: It was important to ensure that enough blank injections were made such that 
no carryover was observed in two blank injections prior to further injections. 
 
               Table 3.1    Example of System Suitability Injection Sequence 
 
 
 
 
Sample No. of Injections 
Blank Minimum of 2 
LIS 1 
Cyclohexanone DSS 1 
PGMMEA DSS 1 
Calibration Control 1 
WS-1 5 
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The 5 separate injections of WS-1 were used to satisfy the system suitability 
requirements for retention times, tailing factors and peak area % RSD given in Table 
3.2.  
Each DSS was injected once. This injection of the DSS was used to satisfy the 
system suitability requirements for DSS signal-to-noise ratio for cyclohexanone and 
PGMMEA given in Table 3.2. 
The analysis could not be carried out if the system suitability criteria listed in Table 
3.2 could not be met. When system suitability criteria could not be met, appropriate 
corrective action had to be taken and the system suitability was repeated. Definitions 
of each term in Table 3.2 can be found in the current USP (United States 
Pharmacopeia 37 2015). 
 
Table 3.2     System Suitability Criteria 
System Suitability Parameter PGMMEA Cyclohexanone 
Retention Time (WS-1) (n = 5) 12.5 ± 1.0 min  13.0 ± 1.0 min 
Tailing Factor (WS-1) (n = 5) ≤  2.0 ≤  2.0 
% RSD for Peak Area (WS-1) (n = 5) NMT 10% NMT 10% 
Resolution between Cyclohexanone and PGMMEA NLT 5 
DSS Signal-to-Noise (n = 1) NLT 20:1 NLT 10:1 
 
 
3.2.8 Method Validation 
The validation tests that were carried out on the specified leachables cyclohexanone 
and PGMMEA were: accuracy, linearity, range, precision (repeatability and 
intermediate), specificity, standard and sample stability, detection limit (DL), 
quantitation limit (QL), and robustness. As no PGMEEA standard was available, the 
validation tests that were carried out on the specified leachable PGMEEA were: 
precision (repeatability and intermediate), robustness and specificity. For this method 
unknown leachables are estimated using cyclohexanone. Since there was no standard 
material available for PGMEEA and due to its structural similarity to PGMMEA, 
PGMMEA was used to estimate PGMEEA in samples. The first test conducted was 
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specificity because if the method was not specific more development would have 
been required. Next, the standard and sample stability was conducted. This would 
enable standards to be used over a number of days during the rest of validation and 
thus would save on preparing fresh standards every day. Robustness was then carried 
out followed by the rest of the validation tests. 
 
3.2.8.1 Specificity 
To demonstrate the specificity of this method in regards to leachable interferences, 
Product X laboratory scale preparation was stressed using the following conditions.  
 Adjusted the pH to approximately 2.5 with 5 N HCL and stored at ambient 
temperature in the dark.   
 Adjusted the pH to approximately 11.5 with 5 N NaOH and stored at ambient 
temperature in the dark.   
 Stored at a temperature of 70oC in the dark 
 Added 5 drops of 30% hydrogen peroxide to 60 mL of sample and stored at 
ambient temperature in the dark. 
 Placed in clear glass and stored in an ICH compliant light chamber until ICH 
light stress guidelines have been met. 
The pH adjusted, heat and hydrogen peroxide stressed samples were stored under 
ambient laboratory conditions and pulled at day-14 and then stored at 2 - 8ºC and 
protected from light until time of analysis. The light stressed samples were pulled 
once ICH guidelines had been met. Control samples were untreated and unstressed 
and then stored in the dark at 2 - 8°C. All control samples were from the same batch 
as the treated and stressed samples. 
The samples were tested using the method to determine if there are any sample 
interferences at the retention times of cyclohexanone, PGMMEA and PGMEEA. 
 
3.2.8.2 Stock Standard Stability 
Stock standard solutions containing cyclohexanone at 1.0% (v/v) and PGMMEA at 
1.0% (v/v) were prepared (in a similar manner as described in Section 3.2.4) in 
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amber glassware on day-0. These solutions were assayed in triplicate and stored 
under ambient laboratory temperature and lighting. Fresh working standards were 
prepared for each day of the study from the stock standards prepared on day-0. These 
standards were then re-assayed against freshly prepared working standards on day-2, 
day-3 and day-7 in order to determine the chemical stability of the stock standard 
solutions in amber glassware. A summary of the data is presented in Tables 3.4 and 
3.5. 
 
3.2.8.3 Intermediate Standard Stability 
Separate intermediate standard solutions containing cyclohexanone and PGMMEA 
were prepared (in a similar manner as described in Section 3.2.4) in amber glassware 
from freshly prepared stock standards and analysed in triplicate on day-0. These 
solutions were stored under ambient laboratory temperature and lighting and re-
assayed against freshly prepared working standards on day-2, day-3 and day-7 in 
order to determine the chemical stability of the intermediate standard solutions in 
amber glassware. A summary of the data is presented in Tables 3.6 and 3.7. 
 
3.2.8.4 Working Standard Stability 
Sufficient working standard solutions containing cyclohexanone and PGMMEA 
were prepared (in a similar manner as described in Section 3.2.4) in amber headspace 
vials from freshly prepared intermediate standards and analysed in triplicate on day-
0. These solutions were stored under ambient laboratory temperature and lighting 
and re-assayed against freshly prepared working standards on day-2, day-3 and day-7 
in order to determine the chemical stability of the working standard solutions in 
amber headspace vials. A summary of the data is presented in Tables 3.8 and 3.9. 
 
3.2.8.5 Cyclohexanone Intermediate DSS Stability  
Intermediate standard solutions were freshly prepared (in a similar manner as 
described in Section 3.2.4) in amber glassware. Separate cyclohexanone intermediate 
DSS solutions were prepared from these working standards and analysed in triplicate 
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on day-0. These solutions were stored under ambient laboratory temperature and 
lighting and re-assayed against freshly prepared cyclohexanone intermediate DSS 
solutions on day-1, day-2, day-3 and day-7 in order to determine the chemical 
stability of the cyclohexanone intermediate DSS solution in amber glassware. A 
summary of the data is presented in Table 3.10. 
 
3.2.8.6 PGMMEA Intermediate DSS Stability  
Intermediate standard solutions were freshly prepared (in a similar manner as 
described in Section 3.2.4) in amber glassware. Separate PGMMEA intermediate 
DSS solutions were prepared from these working standards and analysed in triplicate 
on day-0. These solutions were stored under ambient laboratory temperature and 
lighting and re-assayed against freshly prepared PGMMEA intermediate DSS 
solutions on day-1, day-2, day-3 and day-7 in order to determine the chemical 
stability of the PGMMEA DSS solution in amber glassware. A summary of the data 
is presented in Table 3.11. 
 
3.2.8.7 Cyclohexanone DSS Stability  
Sufficient cyclohexanone DSS solutions were prepared (in a similar manner as 
described in Section 3.2.4) in amber headspace vials from a freshly prepared 
cyclohexanone intermediate DSS and analysed in triplicate on day-0. These solutions 
were stored under ambient laboratory temperature and lighting and re-assayed 
against freshly prepared cyclohexanone DSS solutions on day-1, day-2, day-3 and 
day-7 in order to determine the chemical stability of the cyclohexanone DSS solution 
in amber headspace vials. A summary of the data is presented in Table 3.12. 
 
3.2.8.8 PGMMEA Intermediate DSS Stability  
Sufficient PGMMEA DSS solutions were prepared (in a similar manner as described 
in Section 3.2.4) in amber headspace vials from a freshly prepared PGMMEA 
intermediate DSS and analysed in triplicate on day-0. These solutions were stored 
under ambient laboratory temperature and lighting and re-assayed against freshly 
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prepared PGMMEA DSS solutions on day-1, day-2, day-3 and day-7 in order to 
determine the chemical stability of the PGMMEA DSS solution in amber headspace 
vials. A summary of the data is presented in Table 3.13. 
 
3.2.8.9 Leachable Identification Stock Solution Stability 
Leachable identification stock solution was freshly prepared (in a similar manner as 
described in Section 3.2.4) in amber glassware in triplicate on day-0. These solutions 
were assayed in triplicate and stored under ambient laboratory temperature and 
lighting. Fresh working ID solutions were prepared for each day of the study from 
the stock ID solutions prepared on day-0.  These working ID solutions were then re-
assayed against freshly prepared working ID solutions on day-1, day-2, day-3 and 
day-7 in order to determine the chemical stability of the leachable identification 
stock solution in amber glassware. 
  
3.2.8.10 Leachable Identification Working Solution Stability 
Leachable identification working solutions were freshly prepared (in a similar 
manner as described in Section 3.2.4) in amber headspace vials and analysed in 
triplicate on day-0. These solutions were stored under ambient laboratory 
temperature and lighting and re-assayed on day-1, day-2, day-3 and day-7 in order to 
determine the chemical stability of the leachable identification working solution in 
amber glassware.  
 
3.2.8.11 Sample Stability 
Sample solutions of Product X lab scale preparation were freshly prepared (in a 
similar manner as described in Section 3.2.4) in amber headspace vials on day-0 by 
adding 3 mL of Product X to a vial and capping. Sufficient samples were prepared on 
day-0 to complete the stability study. These solutions were assayed in triplicate and 
stored under ambient laboratory temperature and lighting. Freshly prepared standards 
were used to reanalyse the test sample preparations after day-1, day-2, day-3 and 
day-7.  
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3.2.8.12 Robustness 
Robustness is the reproducibility of the test results for cyclohexanone, PGMMEA 
and PGMEEA obtained by analysis of Product X product under deliberate variations 
of the nominal test conditions. Product X lab scale preparation was spiked with 
tampoprint thinner solution containing approximately 13 ppm cyclohexanone, 13 
ppm PGMMEA and 18 ppm PGMEEA. The method ruggedness (robustness) 
validation is initially demonstrated from the intermediate precision data. Additional 
robustness studies were conducted by analysing the same spiked sample (n = 6) 
using different vial incubation temperatures, transfer line temperatures, final column 
oven temperatures and carrier gas flow rates as shown in Table 3.3.  
 
Each test condition in Table 3.3 was then evaluated for: 
All system suitability data:  Report value 
Retention time and relative retention time of PGMEEA 
Mean cyclohexanone, PGMMEA and PGMEEA, ppm data (n = 6) 
Standard deviation of cyclohexanone, PGMMEA and PGMEEA, ppm data (n = 6) 
% RSD of cyclohexanone, PGMMEA, and PGMEEA, ppm data (n = 6) 
Ratio of the means of cyclohexanone, PGMMEA and PGMEEA, ppm value versus 
nominal conditions (Test 1) where, X1 = Test 1 and X2 = Test 2 - 9 
                
Table 3.3   Robustness Test Conditions 
 Vial Oven 
Temperature 
(ºC) 
Transfer Line 
Temperature 
(ºC) 
Final Column 
Oven  
Temperature 
(ºC) 
Carrier Gas 
Flow  
(mL/min) 
Test 1 * 80 140 245 5.0 
Test 2 75 140 245 5.0 
Test 3 85 140 245 5.0 
Test 4 80 135 245 5.0 
Test 5 80 145 245 5.0 
Test 6 80 140 235 5.0 
Test 7 80 140 255 5.0 
Test 8 80 140 245 4.5 
Test 9 80 140 245 5.5 
*Represents nominal analysis conditions of the method 
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The method robustness tests 1 - 9 given in Table 3.3 were conducted and the 
resultant data is provided in Tables 3.14 to 3.18. The mean cyclohexanone (ppm), 
PGMMEA (ppm) and PGMEEA (ppm) data from robustness test 1 was used to 
determine the ratio of the means results for robustness tests 2 – 9 in Tables 3.16 to 
3.18. 
 
3.2.8.13 Accuracy of Cyclohexanone 
Product X lab scale preparation was spiked with cyclohexanone at approximately 
0.5, 1, 2, 10, 20 and 30 ppm. These levels are equivalent to 2.5%, 5%, 10%, 25%, 
50%, 100% and 150% of cyclohexanone proposed product specification, 
respectively.  Three separate preparations were analysed for the 5%, 10%, 25%, 50% 
and 150% levels, whereas six separate preparations were analysed for the 2.5% and 
100% levels.  The ppm concentration of cyclohexanone was calculated for each 
preparation.  The cyclohexanone accuracy results are reported in Table 3.19. 
 
3.2.8.14 Accuracy of PGMMEA 
Product X lab scale preparation was spiked with PGMMEA at approximately 2, 5, 
10, 20 and 30 ppm PGMMEA. These accuracy levels are equivalent to 10%, 25%, 
50%, 100%, and 150% of PGMMEA proposed product specification, respectively.  
Three separate preparations were analysed for the 25%, 50% and 150% levels, 
whereas six separate preparations were analysed for the 10% and 100% levels. The 
ppm concentration of PGMMEA was calculated for each preparation. The 
PGMMEA accuracy results are reported in Table 3.20. 
 
3.2.8.15 Cyclohexanone Linearity 
To determine linearity for cyclohexanone, a linearity curve was generated from 0.5 to 
30.0 ppm cyclohexanone.  This range is equivalent to approximately 2.5 to 150% of 
the cyclohexanone proposed product specification.  Each concentration point was run 
in triplicate, except for the 2.5% and 100% target solution which were run 6 times 
(separate preparations). The y-intercept at the origin for peak area data is less than 
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5% of the y-intercept at label strength, indicating that a single point calibration can 
be used. Table 3.21 contains the linearity data.  A summary of the data can be seen in 
Table 3.22.  
 
3.2.8.16 PGMMEA Linearity 
To determine linearity for PGMMEA, a linearity curve was generated from 2.0 to 
30.0 ppm PGMMEA.  This range is equivalent to approximately 10% to 150% of the 
PGMMEA proposed product specification.  Each concentration point was run in 
triplicate, except for the 10% and 100% target solution which were run 6 times 
(separate preparations). The y-intercept at the origin for peak area data is less than 
5% of the y-intercept at label strength (this is an in-house specification as regulatory 
agencies do not set a specification other than to report value), indicating that a single 
point calibration can be used. Table 3.23 contains the linearity data.  A summary of 
the data can be seen in Table 3.24.  
 
3.2.8.17 Cyclohexanone and PGMMEA Standard Precision (Repeatability) 
Standard precision was determined by injecting 6 replicate injections of 
cyclohexanone and PGMMEA working standard. A summary of the data is shown in 
Table 3.25. 
 
3.2.8.18 Cyclohexanone, PGMMEA and PGMEEA Sample Precision (Repeatability) 
Sample precision was determined by injecting a Tampoprint thinner spiked Product 
X laboratory scale preparation containing approximately 13 ppm cyclohexanone, 13 
ppm PGMMEA and 18 ppm PGMEEA. A summary of the data is shown in Table 
3.26. 
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3.2.8.19 Cyclohexanone, PGMMEA and PGMEEA Operator-A Day-1/Day-2 
(Intermediate Precision) 
Six separate preparations of Product X, spiked with Tampoprint thinner solution 
containing approximately 13 ppm cyclohexanone and PGMMEA and 18 ppm 
PGMEEA were analysed and the amount of cyclohexanone, PGMMEA and 
PGMEEA (ppm) determined by operator-A. On day-2 (operator-A) analysed the 
same spiked sample to provide information concerning day-to-day precision. The 
same instrument and column were used on both days. A summary of the data is 
shown in Tables 3.27 to 3.29. 
A second operator (operator-B) analysed the same spiked product to provide 
information concerning operator-to-operator precision. Operator B used a different 
instrument and different column lot number to operator A. A summary of the data is 
shown in Tables 3.27 to 3.29. 
 
3.2.8.20 Range 
The range is the interval between the lower and upper concentration of analyte in the 
sample for which it has been demonstrated that the analytical procedure has a 
suitable level of precision, accuracy and linearity. The range was established through 
accuracy, linearity and precision. 
 
3.2.8.21 DL Determination for Cyclohexanone and PGMMEA 
The DL of cyclohexanone and the DL of PGMMEA in Product X were determined 
by preparing a single solution of Product X lab scale preparation spiked at 0.2 ppm 
with cyclohexanone and 1.0 ppm with PGMMEA. From this solution 3 separate 
preparations were analysed. A summary of DL data is given in Table 3.30.   
 
3.2.8.22 QL Determination for Cyclohexanone and PGMMEA  
The QL of cyclohexanone and the QL of PGMMEA in Product X were determined 
by preparing a single solution of Product X lab scale preparation spiked at 0.5 ppm 
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with cyclohexanone and 2.0 ppm with PGMMEA. From this solution 6 separate 
preparations were analysed. A summary of the QL data is given in Table 3.31.  
 
3.2.9 Sample Analysis 
Injections of the working standard (WS-1) were used for bracketing after every six 
samples.  
 
3.3 Results and Discussion 
 
3.3.1 Rationale for Procedure 
This method has been validated for the quantitation of the specified Tampoprint 
leachables cyclohexanone, PGMMEA and PGMEEA. Results from all the validation 
tests are recorded in the following tables. 
This method was validated to the current USP Category II (United States 
Pharmacopeia 37 2015) for cyclohexanone, PGMMEA and PGMEEA. The 
validation also complies with ICH Q2 (R1) (International Conference of 
Harmonisation 2005) for assay and impurities. 
 
3.3.2 Specificity  
There were no peaks observed at the retention times of PGMMEA and PGMEEA. 
There was a peak detected at the retention time of cyclohexanone in the stressed 
samples. However, this peak had a signal to noise of considerably less than 10:1 and 
therefore meets the acceptance criteria. No significant change in the chromatographic 
profile of the stressed samples was seen when compared with that of the control. The 
method is deemed to be specific for the determination of container closure leachables 
in Product X. 
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3.3.3 Standard Stability 
3.3.3.1 Stock Standard Stability  
Table 3.4     Cyclohexanone Stock Standard Stability – Amber Glassware 
 Day-0 Day-2 Day-3 Day-7 
Mean cyclohexanone ppm 18.58 19.20 19.11 19.09 
SD ppm 5.4 × 10
-1
 7.4 × 10
-1
 2.8 × 10
-1
 4.1 × 10
-1
 
% RSD ppm 2.9 3.8 1.4 2.1 
n 3 3 3 3 
Ratio of the means 
cyclohexanone ppm values 
(vs. day-0) 
N/A 1.033 1.028 1.027 
 
Table 3.5     PGMMEA Stock Standard Stability – Amber Glassware 
 Day-0  Day-2 Day-3 Day-7 
Mean PGMMEA ppm 18.97 19.95 19.89 19.92 
SD ppm 5.5 × 10
-1
 7.9 × 10
-1
 3.5 × 10
-1
 5.7 × 10
-1
 
% RSD ppm 2.9 3.9 1.7 2.9 
n 3 3 3 3 
Ratio of the means PGMMEA 
ppm values (vs. day-0) 
N/A 1.051 1.048 1.050 
 
The acceptance criterion for this study is that the ratio of mean values for 
cyclohexanone and PGMMEA for the stock standard data remains within 0.7 and 1.3 
throughout the testing period. Based on the data, the stock standard is stable for up to 
7 days when stored in amber glassware. 
 
3.3.3.2 Intermediate Standard Stability 
Table 3.6    Cyclohexanone Intermediate Standard Stability – Amber Glassware  
 Day-0 Day-2 Day-3 Day-7 
Mean cyclohexanone ppm 18.58 18.64 18.16 18.90 
SD ppm 5.4 × 10
-1
 1.1 x 10
0
 1.9 x 10
-1
 8.2 x 10
-1
 
% RSD ppm 2.9 5.9 1.0 4.3 
n 3 3 3 3 
Ratio of the means 
cyclohexanone ppm values 
(vs. day-0) 
N/A 1.003 0.977 1.017 
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Table 3.7    PGMMEA Intermediate Standard Stability – Amber Glassware 
 Day-0 Day-2 Day-3 Day-7 
Mean PGMMEA ppm 18.97 19.35 18.86 19.75 
SD ppm 5.5 × 10
-1
 1.1 x 10
0
 2.3 x 10
-1
 9.4 x 10
-1
 
% RSD ppm 2.9 6.0 1.2 4.8 
n 3 3 3 3 
Ratio of the means PGMMEA 
ppm values (vs. day-0) 
N/A 1.020 0.994 1.041 
 
The acceptance criterion for this study is that the ratio of mean values for the 
cyclohexanone and the PGMMEA for the intermediate standard data remains within 
0.7 and 1.3 throughout the testing period. Based on the data, the intermediate 
standard is stable for up to 7 days when stored in amber glassware. 
 
3.3.3.3 Working Standard Stability 
Table 3.8     Cyclohexanone Working Standard Stability – Amber Headspace 
Vials  
 Day-0 Day-2 Day-3 Day-7 
Mean cyclohexanone ppm 18.58 18.23 18.42 19.26 
SD ppm 5.4 × 10
-1
 4.7 x 10
-1
 3.8 x 10
-1
 7.5 x 10
-1
 
% RSD ppm 2.9 2.6 2.0 3.9 
n 3 3 3 3 
Ratio of the means 
cyclohexanone ppm values 
(vs. day-0) 
N/A 0.981 0.991 1.036 
 
Table 3.9     PGMMEA Working Standard Stability – Amber Headspace Vials 
 Day-0 Day-2 Day-3 Day-7 
Mean PGMMEA ppm 18.97 18.81 19.02 20.03 
SD ppm 5.5 × 10
-1
 5.5 x 10
-1
 4.9 x 10
-1
 7.6 x 10
-1
 
% RSD ppm 2.9 2.9 2.6 3.7 
n 3 3 3 3 
Ratio of the means PGMMEA 
ppm values (vs. day-0) 
N/A 0.991 1.002 1.055 
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The acceptance criterion for this study is that the ratio of mean values for the 
cyclohexanone and the PGMMEA for the working standard data remains within 0.7 
and 1.3 throughout the testing period. Based on the data, the working standard is 
stable for up to 7 days when stored in amber headspace vials. 
 
3.3.3.4 Cyclohexanone Intermediate DSS Stability 
Table 3.10      Cyclohexanone Intermediate DSS Stability in Amber Glassware  
                        (n = 3) 
 Day-0 Day-1 Day-2 Day-3 Day-7 
Mean S/N DSS 23.3:1 24.5:1 26.8:1 29.1:1 18.9:1 
S/N SD 6.0 × 10
0
 6.1 × 10
-1
 1.0 × 10
0
 4.4 × 10
0
 6.4 × 10
-1
 
S/N % RSD  25.9 2.4 4.0 15.2 3.4 
Mean cyclohexanone peak 
area 
3.92 3.20 3.37 3.66 3.37 
SD peak area 1.5 × 10
-1
 9.4 × 10
-2
 1.8 × 10
-1
 1.7 × 10
-1
 1.7 × 10
-1
 
% RSD peak area  3.9 2.9 5.3 4.7 5.2 
Mean % Recovery DSS 108.4 102.0 112.6 119.4 110.0 
% Recovery SD 4.2 × 10
0
 2.9 × 10
0
 6.0 × 10
0
 5.7 × 10
0
 5.7 × 10
0
 
% Recovery % RSD  3.9 2.9 5.3 4.7 5.2 
Ratio of the means % 
Recovery values (vs. day-0) 
N/A 0.940 1.038 1.101 1.014 
 
The acceptance criterion for this study is that the ratio of means for the 
cyclohexanone intermediate DSS data remains within 0.7 and 1.3 throughout the 
testing period. Based on the data, the cyclohexanone intermediate DSS is stable for 
up to 7 days when stored in amber glassware.  
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3.3.3.5 PGMMEA Intermediate DSS Stability  
Table 3.11    PGMMEA Intermediate DSS Stability in Amber Glassware (n = 3) 
 Day-0 Day-1 Day-2 Day-3 Day-7 
Mean S/N DSS 32.8:1 50.9:1 54.1:1 47.5:1 34.5:1 
S/N SD 1.7 × 10
0
 2.7 × 10
0
 7.7 × 10
0
 7.0 × 10
-1
 5.7 × 10
-1
 
S/N % RSD  5.3 5.4 14.3 14.7 1.6 
Mean PGMMEA peak area 7.61 6.27 6.60 6.58 6.63 
SD peak area 3.0 × 10
-1
 2.2 × 10
-1
 8.0 × 10
-2
 2.7 × 10
-1
 1.3 × 10
-1
 
% RSD peak area 4.0 3.5 1.2 4.2 2.0 
Mean % Recovery DSS 94.4 102.1 105.4 102.2 102.5 
% Recovery SD 3.8 × 10
0
 3.6 × 10
0
 1.2 × 10
0
 4.3 × 10
0
 2.1 × 10
0
 
% Recovery % RSD  4.0 3.5 1.2 4.2 2.0 
Ratio of the means % 
Recovery values (vs. day-0) 
N/A 1.081 1.116 1.082 1.085 
 
The acceptance criterion for this study is that the ratio of means for the intermediate 
PGMMEA DSS data remains within 0.7 and 1.3 throughout the testing period. Based 
on the data, the intermediate PGMMEA DSS is stable for up to 7 days when stored in 
amber glassware. 
3.3.3.6 Cyclohexanone DSS Stability  
Table 3.12    Cyclohexanone DSS Stability in Amber Headspace Vials (n = 3) 
 Day-0 Day-1 
Mean S/N DSS 23.3:1 13.9:1 
S/N SD 6.0 × 100 1.4 × 10
0
 
S/N % RSD  25.9 3.9 
Mean cyclohexanone peak area 3.922 4.130 
SD peak area 1.5 × 10-1 5.5 × 10-2 
% RSD peak area 3.9 1.3 
Mean % Recovery DSS 108.41 131.60 
% Recovery SD 4.2 × 100 1.7 × 100 
% Recovery % RSD  3.9 1.3 
Ratio of the means % Recovery 
values (vs. day-0) 
N/A 1.213 
 
The acceptance criterion for this study is that the ratio of means for the 
cyclohexanone DSS data remains within 0.7 and 1.3 throughout the testing period. 
However, the mean cyclohexanone DSS % recovery fails to meet the 80.0 – 120.0% 
recovery acceptance criterion. Based on the data, the cyclohexanone DSS must be 
prepared fresh on the day of analysis. 
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3.3.3.7 PGMMEA DSS Stability  
Table 3.13    PGMMEA DSS Stability in Amber Headspace Vials (n = 3) 
 Day-0 Day-1 
Mean S/N DSS 32.8:1 78.8:1 
S/N SD 1.7 × 100 5.4 × 100 
S/N % RSD  5.3 6.9 
Mean PGMMEA peak area 7.609 8.640 
SD peak area 3.0 × 10-1 5.7 × 10-1 
% RSD peak area 4.0 6.6 
Mean % Recovery DSS 94.37 140.73 
% Recovery SD 3.8 × 100 9.32 × 100 
% Recovery % RSD  4.0 6.6 
Ratio of the means % Recovery 
values (vs. day-0) 
N/A 1.491 
 
The acceptance criterion for this study is that the ratio of means for the PGMMEA 
DSS data remains within 0.7 and 1.3 throughout the testing period. However, the 
mean PGMMEA DSS % recovery fails to meet the 80.0 – 120.0% recovery 
acceptance criterion. The ratio of the means value of 1.5 also fails. Based on the data, 
the PGMMEA DSS must be prepared fresh on the day of analysis. 
 
3.3.3.8 Leachable Identification Working Solution Stability 
The acceptance criterion for this study is that there is no significant change in the 
chromatographic profile of the sample solution between day-0 and day-1, day-3 and 
day-7. No deterioration of chromatography or shift in retention time has occurred for 
the cyclohexanone, PGMMEA and PGMEEA peaks throughout the testing period. 
Based on the data, the leachable identification working solution is stable for up to 7 
days when stored in amber glassware. 
 
3.3.4 Sample Stability 
The acceptance criterion for this study is that there is no significant change in the 
chromatographic profile of the sample solution between day-0 and day-1, day-2, day-
3 and day-7. Sample degradation has not produced any additional peaks that are 
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visible on the baseline that could interfere with the detection of any potential 
leachables.  
Based on test results, sample preparations of Product X are stable for 7 days when 
stored at ambient laboratory temperature and lighting in amber headspace vials. 
 
3.3.5 Robustness 
Table 3.14   Cyclohexanone Robustness System Suitability Data 
 Retention Time 
Cyclohexanone 
(min) 
Tailing Factor 
Cyclohexanone 
Resolution 
between 
Cyclohexanone 
and PGMMEA 
Signal-to-Noise 
Cyclohexanone 
% RSD 
Cyclohexanone 
Peak Area  
Acceptance 
Criteria 
Report Report Report Report ≤ 10% 
Test 1 * 13.01 1.37 7.7 24.5:1 1.2 
Test 2 13.00 1.38 7.4 14.6:1 0.6 
Test 3 12.99 1.37 7.6 17.1:1 5.7 
Test 4 12.98 1.34 7.7 17.5:1 2.4 
Test 5 12.98 1.34 7.6 22.9:1 6.4 
Test 6 12.97 1.35 7.6 17.2:1 3.7 
Test 7 12.97 1.33 7.7 13.9:1 5.2 
Test 8 13.27 1.27 7.8 15.1:1 2.1 
Test 9 12.70 1.38 7.4 18.6:1 3.0 
*Represents nominal analysis conditions of the method 
 
Retention Time (tR) 
The time taken after injection for the analyte molecules to reach the detector. This 
dependent on the column flow rate, column capacity, extra column dead volume and 
the retardation factor of the molecules on the stationary phase. 
 
Tailing Factor  
A measure of how close a chromatographic peak is to a symmetrical shape. As a 
peak slopes the tailing factor increases. 
Tf = ac / 2ab 
where ac is the peak width at 5% of the peak height, and ab is the front half-width 
measured from the leading edge to a perpendicular dropped from the peak apex. 
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Resolution 
A characteristic of the separation of two adjacent peaks. It may be expressed 
according to the equation: 
RAB = 2 |dR(B) - dR(A)| 
                |w(B) + w(A)| 
where RAB is the resolution, dR(A) and dR(B) are the retention distances (time or 
volume) of each eluted component A and B, and w(A) and w(B) are the respective 
widths of each peak at its base. 
 
 Table 3.15   PGMMEA Robustness System Suitability Data 
 Retention Time 
PGMMEA 
(min) 
Tailing Factor 
PGMMEA 
% RSD 
PGMMEA 
Peak Area 
Signal-to-Noise 
PGMMEA 
Acceptance  
Criteria 
Report Report ≤ 10% Report 
Test 1 * 12.58 2.21 1.2 24.7:1 
Test 2 12.58 2.19 0.9 21.7:1 
Test 3 12.56 2.13 5.7 27.6:1 
Test 4 12.55 2.02 2.3 29.0:1 
Test 5 12.55 2.02 6.9 28.4:1 
Test 6 12.55 2.00 4.2 26.9:1 
Test 7 12.53 1.92 5.3 26.6:1 
Test 8 12.83 1.79 2.5 32.6:1 
Test 9 12.29 2.03 2.9 31.5:1 
*Represents nominal analysis conditions of the method 
 
 Table 3.16   Cyclohexanone Robustness Data 
 Mean 
Cyclohexanone 
(ppm) 
SD  
Cyclohexanone 
(ppm) 
% RSD 
Cyclohexanone 
(ppm) 
Ratio of the 
Means 
Cyclohexanone 
Acceptance 
Criteria 
Report Report ≤ 10% 0.7 – 1.3 
Test 1 * 13.85 4.1 × 10-1 3.0 N/A 
Test 2 14.18 3.9 × 10-1 2.7 1.0 
Test 3 14.79 9.1 × 10-1 6.2 1.1 
Test 4 13.31 2.1 × 10-1 1.6 1.0 
Test 5 15.08 5.0 × 100 3.3 1.1 
Test 6 15.03 1.6 × 10-1 1.0 1.1 
Test 7 14.30 2.9 × 10-1 2.0 1.0 
Test 8 14.19 5.8 × 10-1 4.1 1.0 
Test 9 13.84 4.3 × 10-2 3.1 1.0 
*Represents nominal analysis conditions of the method 
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Table 3.17   PGMMEA Robustness Data 
 Mean 
PGMMEA 
(ppm) 
SD 
PGMMEA 
(ppm) 
% RSD 
PGMMEA 
(ppm) 
Ratio of the 
Means 
PGMMEA 
Acceptance 
Criteria 
Report Report ≤ 10% 0.7 – 1.3 
Test 1 * 13.31 4.5 × 10-1 3.4 N/A 
Test 2 13.60 3.8 × 10-1 2.8 1.0 
Test 3 14.24 9.7 × 10-1 6.8 1.1 
Test 4 12.78 1.7 × 10-1 1.3 1.0 
Test 5 14.64 5.3 × 10-1 3.6 1.1 
Test 6 13.92 2.0 × 10-1 1.4 1.0 
Test 7 13.69 2.7 × 10-1 2.0 1.0 
Test 8 13.69 6.4 × 10-1 4.7 1.0 
Test 9 13.26 4.7 × 10-2 3.5 1.0 
*Represents nominal analysis conditions of the method 
 
 Table 3.18   PGMEEA Robustness Data 
 Retention 
Time 
PGMEEA 
(min) 
Relative 
Retention 
Time 
PGMEEA 
Mean 
PGMEEA 
(ppm) 
SD 
PGMEEA 
(ppm) 
% RSD 
PGMEEA 
(ppm) 
Ratio of the 
Means 
PGMEEA 
Acceptance 
Criteria 
Report Report Report Report ≤ 10% 0.7 – 1.3 
Test 1 * 13.56 1.04 18.09 5.5 × 10-1 3.0 N/A 
Test 2 13.55 1.04 17.29 3.3 × 10-1 1.9 1.0 
Test 3 13.54 1.04 18.95 1.4 × 100 7.7 1.0 
Test 4 13.54 1.04 16.95 6.2 × 10-1 3.6 1.0 
Test 5 13.53    1.04 19.53 6.7 × 10-1 3.4 1.1 
Test 6 13.53 1.03 19.65 5.4 × 10-1 2.7 1.1 
Test 7 13.53 1.04 18.28 3.9 × 10-1 2.1 1.0 
Test 8 13.80 1.03 18.40 9.1 × 100 5.3 1.0 
Test 9 13.30 1.04 17.76 7.2 × 100 4.0 1.0 
*Represents nominal analysis conditions of the method 
Conclusion of Robustness Study 
The data indicates that all System Suitability criteria were met for all challenges. The 
method is capable of withstanding: 
 ± 5°C variation in vial oven temperature 
 ± 5°C variation in transfer line temperature 
 ± 10°C variation in final oven temperature  
 ± 0.5 mL/min change in carrier gas flow 
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Overall, the method is considered robust and suitable for routine use where accurate 
and reliable quantitative data is required for cyclohexanone, PGMMEA, PGMEEA 
and other potential leachables.  
The information derived from the precision section provides an additional measure of 
method ruggedness. Using different analysts, on different days and different columns 
will yield chromatography and quantitative cyclohexanone, PGMMEA and 
PGMEEA values that are very consistent. This demonstrates that the method is 
sufficiently rugged, reproducible and robust under conditions of routine laboratory 
usage. 
 
3.3.6  Accuracy  
3.3.6.1 Product X Placebo Interferences  
Three replicate injections of Product X lab scale preparation showed no interferences 
with a S/N ratio greater than 10:1 at the location of the cyclohexanone, PGMMEA 
and PGMEEA peaks.  This lack of placebo interference meets the acceptance 
criteria.  
3.3.6.2 Accuracy Data for Cyclohexanone 
Table 3.19  Accuracy Data for Cyclohexanone 
Cyclohexanone  
Conc. ppm 
0.5 1 2 5 10 20 30 
Conc. ppm 0.48 
0.50 
0.53 
0.47 
0.45 
0.48 
0.94 
0.93 
0.99 
1.87 
1.85 
1.89 
4.58 
4.73 
4.75 
 
9.44 
9.05 
8.64 
20.02 
19.24 
18.93 
18.39 
19.06 
19.09 
29.72 
29.21 
28.30 
Mean Conc. ppm 0.49 0.96 1.87 4.69 9.05 19.13 29.08 
SD, Conc. ppm 2.5 × 10
-2
 3.1 × 10
-2
 1.8 × 10
-2
 9.0 × 10
-2
 4.0 × 10
-1
 5.2 × 10
-1
 7.1 × 10
-1
 
% RSD, Conc. ppm 5.1 3.2 0.9 1.9 4.4 2.4 2.4 
% Recovery 102.42 
105.59 
112.14 
100.73 
96.30 
102.21 
99.36 
98.73 
104.75 
98.94 
98.04 
99.94 
96.87 
100.04 
100.33 
99.71 
95.58 
91.23 
105.71 
101.59 
99.98 
97.09 
100.65 
100.83 
104.62 
102.83 
99.63 
 
Mean % Recovery 103.2 100.9 99.0 99.1 95.5 101.0 102.4 
SD, % Recovery 5.3 × 10
0
 3.3 × 10
0
 9.5 × 10
-1
 1.9 × 10
0
 4.2 × 10
0
 2.7 × 10
0
 2.5 × 10
0
 
% RSD, % Recovery 5.1 3.2 0.9 1.9 4.4 2.7 2.4 
n  6 3 3 3 3 6 3 
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The mean accuracy values obtained meets the acceptance criteria of 80.0% - 
120.0%.  The individual accuracy requirement of 70.0% - 130.0% was also met 
for each individual preparation.   
 
3.3.6.3 Accuracy Data for PGMMEA 
Table 3.20       Accuracy Data for PGMMEA 
PGMMEA 
Conc. ppm 
2 5 10 20 30 
Conc. ppm 1.83 
1.86 
1.87 
1.89 
1.77 
1.94 
4.58 
4.72 
4.69 
 
 
9.48 
9.13 
8.65 
20.72 
19.60 
19.18 
18.54 
19.33 
19.32 
30.36 
30.09 
28.79 
Mean Conc. ppm 1.86 4.67 9.09 19.45 29.75 
SD, Conc. ppm 5.6 × 10
-2
 7.3 × 10
-2
 4.1 × 10
-1
 7.1 × 10
-1
 8.4 × 10
-1
 
% RSD, Conc. ppm  3.0 1.5 4.6 3.6 2.8 
% Recovery 94.74 
96.08 
96.70 
97.42 
91.39 
100.15 
94.55 
97.46 
96.74 
97.76 
94.13 
89.17 
106.81 
101.06 
98.90 
95.57 
99.64 
99.59 
104.33 
103.43 
98.93 
Mean % Recovery 96.1 96.3 93.7 100.3 102.2 
SD, % Recovery 2.9 × 10
0
 1.5 × 10
0
 4.3 × 10
0
 3.6 × 10
0
 2.8 × 10
0
 
% RSD, % Recovery 3.0 1.5 4.6 3.6 2.8 
n  6 3 3 6 3 
 
The mean accuracy values obtained meets the acceptance criteria of 80.0% - 
120.0%.  The individual accuracy requirement of 70.0% - 130.0% was also met 
for each individual preparation.   
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3.3.7 Linearity 
3.3.7.1 Cyclohexanone Linearity  
Table 3.21     Cyclohexanone Linearity Concentrations and Peak Areas 
Concentration (ppm) Peak Area % Specification Limit  
0.5 3.21 2.5 
0.5 3.02 2.5 
0.5 3.16 2.5 
0.5 3.52 2.5 
0.5 3.32 2.5 
0.5 3.21 2.5 
1.0 6.41 5 
1.0 6.03 5 
1.0 6.08 5 
2.0 13.01 10 
2.0 12.76 10 
2.0 12.87 10 
5.0 34.23 25 
5.0 34.13 25 
5.0 33.06 25 
10.0 62.26 50 
10.0 65.23 50 
10.0 68.05 50 
20.0 134.60 100 
20.0 134.36 100 
20.0 129.60 100 
20.0 133.45 100 
20.0 135.61 100 
20.0 141.10 100 
30.0 192.59 150 
30.0 198.78 150 
30.0 202.25 150 
 
Table 3.22     Linearity for Cyclohexanone Data Summary  
Parameter Values 
Correlation Coefficient, r 0.999 
Y-intercept, Y0 -0.088 
Y at label strength, Y100 135 
% Y0/Y100 = (Y0/Y100) x 100% 0.06 
Slope, m 6.66 
Residual Sum of Squares 170 
Regression Equation y = 6.66(x) + (-0.088) 
Linearity requirements for cyclohexanone have been established and meet the 
acceptance criteria of NMT 2% for y intercept.  
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Figure 3.4: Linearity Plot of Cyclohexanone from 0.5 – 30.0 ppm, Equivalent to 2.5 
– 150% of Cyclohexanone Product Specification 
 
The graph in Figure 3.4 shows a best fit line for the average of each set of replicates. 
There are 6 replicates for the 0.5 and 20 ppm concentrations and 3 replicates for the 
remaining concentrations. 
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3.3.7.2 PGMMEA Linearity  
Table 3.23      PGMMEA Linearity Concentrations and Peak Areas 
Concentration (ppm) Peak Area % Specification Limit  
2.0 6.98 10 
2.0 6.37 10 
2.0 6.79 10 
2.0 6.74 10 
2.0 6.70 10 
2.0 6.61 10 
5.0 17.82 25 
5.0 17.95 25 
5.0 17.42 25 
10.0 32.86 50 
10.0 34.69 50 
10.0 36.02 50 
20.0 71.61 100 
20.0 71.65 100 
20.0 68.72 100 
20.0 71.11 100 
20.0 72.67 100 
20.0 76.80 100 
30.0 102.07 150 
30.0 106.71 150 
30.0 107.64 150 
 
 
Table 3.24  Linearity for PGMMEA Data Summary 
Parameter Values 
Correlation Coefficient, r 0.998 
Y-intercept, Y0 -0.265 
Y at label strength, Y100 72.1 
% Y0/Y100 = (Y0/Y100) x 100% 0.36 
Slope, m 3.56 
Residual Sum of Squares 72.1 
Regression Equation y = 3.56(x) + (-0.265) 
 
Linearity requirements for PGMMEA have been established and meet the acceptance 
criteria of NMT 2% for y intercept.  
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Linearity Plot of PGMMEA Concentration (ppm) versus PGMMEA Peak Area
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Figure 3.5: Linearity Plot of PGMMEA from 2.0 – 30.0 ppm, Equivalent to  
                    10 – 150% of PGMMEA Product Specification  
 
The graph in Figure 3.5 shows a best fit line for the average of each set of replicates. 
There are 6 replicates for the 2.0 and 20 ppm concentrations and 3 replicates for the 
remaining concentrations. 
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3.3.8 Precision (Repeatability and Intermediate Precision) 
3.3.8.1 Cyclohexanone and PGMMEA Standard Precision (Repeatability) 
Table 3.25     Cyclohexanone and PGMMEA Standard Precision Data 
The % RSD meets the acceptance criterion of ≤ 10%. 
 
3.3.8.2 Cyclohexanone, PGMMEA and PGMEEA Sample Precision (Repeatability) 
Table 3.26      Cyclohexanone, PGMMEA and PGMEEA Sample Precision Data 
The % RSD meets the acceptance criterion of ≤ 10%. 
 
3.3.8.3 Cyclohexanone, PGMMEA and PGMEEA Operator-A Day-1/Day-2 
(Intermediate Precision) 
Table 3.27    Cyclohexanone Day-to-Day Intermediate Precision Data 
Parameter Operator-A 
Day-1 
Operator-A 
Day-2 
Operator-B 
 
Mean ppm 14.43 13.85 15.11 
SD ppm 4.1 × 10-1 4.1 × 10-1 7.7 × 10-1 
% RSD ppm 2.9 3.0 5.1 
n 6 6 6 
Confidence interval 14.43 ± 0.43 13.85 ± 0.43 15.11 ± 0.81 
Ratio of the means,  
operator-A day-2/day-1 
1.0 
Ratio of the means,  
operator-B/operator-A day-1 
1.0 
Parameter Cyclohexanone Results PGMMEA Results 
Mean peak area 150.72 82.62 
SD peak area 6.0 3.6 
% RSD peak area 4.0 4.3 
n 6 6 
Confidence interval 150.72 ± 6.3 82.62 ± 3.7 
Parameter Cyclohexanone 
Results 
PGMMEA 
Results 
PGMEEA Results 
Mean ppm 14.43 13.82 18.12 
SD ppm 4.1 × 10-1 4.3 × 10-1 5.9 × 10-1 
% RSD ppm 2.9 3.1 3.2 
n 6 6 6 
Confidence 
interval 
14.43 ± 0.43 13.82 ± 0.45 18.12 ± 0.62 
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Table 3.28     PGMMEA Day-to-Day Intermediate Precision Data 
Parameter Operator-A 
Day-1 
Operator-A 
Day-2 
Operator-B 
 
Mean ppm 13.82 13.31 14.13 
SD ppm 4.3 × 10-1 4.5 × 10-1 7.3 × 10-1 
% RSD ppm 3.1 3.4 5.2 
n 6 6 6 
Confidence interval 13.82 ± 0.45 13.31 ± 0.47 14.13 ± 0.77 
Ratio of the means,  
operator-A day-2/day-1 
1.0 
Ratio of the means,  
operator-B/operator-A day-1 
1.0 
 
 
Table 3.29    PGMEEA Day-to-Day Intermediate Precision Data 
Parameter Operator-A 
Day-1 
Operator-A 
Day-2 
Operator-B 
 
Mean ppm 18.12 18.09 18.37 
SD 5.9 × 10-1 5.5 × 10-1 6.4 × 10-1 
% RSD  3.2 3.0 3.4 
n 6 6 6 
Confidence interval 18.12 ± 0.62 18.09 ± 0.58 18.37 ± 0.67 
Ratio of the means,  
operator-A day-2/day-1 
1.0 
Ratio of the means,  
operator-B/operator-A day-1 
1.0 
The ratio of the means value (ppm) for cyclohexanone, PGMMEA and PGMEEA 
meets the acceptance criterion of between 0.7 and 1.3 for cyclohexanone, PGMMEA 
and PGMEEA intermediate precision. The % RSD values meet the acceptance 
criterion of % RSD ≤ 10.0 for n = 6. 
 
3.3.9 Range 
The range for cyclohexanone has been established from 0.5 ppm to 30.0 ppm which 
corresponds to 2.5 to 150% of the proposed product specification. The range for 
PGMMEA has been established from 2.0 ppm to 30.0 ppm which corresponds to 10 
to 150% of the working standard concentration. This was achieved through 
measurements for accuracy, linearity and precision. 
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3.3.10 Detection Limit (DL) 
DL Determination for Cyclohexanone and PGMMEA 
Table 3.30    DL of Cyclohexanone and PGMMEA in Product X 
Parameter Cyclohexanone Results PGMMEA Results 
Mean ppm 0.23 0.92 
Mean S/N Ratio 6.3:1 15.5:1 
% RSD of Peak Height 8.2 5.7 
n 3 3 
Based upon the data shown in Table 3.30, the DL for cyclohexanone is determined to 
be 0.2 ppm and the DL for PGMMEA is determined to be 1.0 ppm.  
 
3.3.11 Quantitation Limit (QL) 
QL Determination for Cyclohexanone and PGMMEA  
Table 3.31    QL of Cyclohexanone and PGMMEA in Product X 
Parameter Cyclohexanone Results PGMMEA Results 
Mean ppm 0.49 1.86 
Mean % Recovery 103.2 96.1 
Mean S/N Ratio 18.1:1 38.4:1 
% RSD of Peak Height 7.4 3.5 
n 6 6 
 
Based upon the data shown in Table 3.31, the QL for cyclohexanone is determined to 
be 0.5 ppm and the QL for PGMMEA is determined to be 1.9 ppm.   
Mean % recovery of both cyclohexanone and PGMMEA also meets the acceptance 
criteria of 100.0% ± 20.0%. 
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3.4 Conclusion 
The concentration of container closure leachables are determined by pipetting 3 mL 
of sample into a headspace vial, capping and injecting a portion of the headspace 
onto the gas chromatographic DB-5 capillary column. Volatile and semi-volatile 
organic compounds are detected using a flame ionisation detector (FID). A 
temperature program is incorporated which allows the separation of potential volatile 
compounds from higher boiling compounds. The ability of the FID to detect virtually 
any volatile or semi-volatile organic compound with a carbon-hydrogen bond makes 
it ideal for this ‘finger printing’ comparison test which will detect a wide variety of 
potential organic leachables and is sensitive down to less than 1 ppm for common 
organic solvents. The method employs a standard additions technique, whereby, 
working standards are prepared by directly spiking cyclohexanone and propylene 
glycol monomethyl ether acetate solution into 3 mL of sample. This technique 
requires the use of a ‘calibration control’ which is product injected neat to account 
for any interference that may occur at the retention time of cyclohexanone or 
PGMMEA in the working standards. 
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Chapter 4: Final Conclusions 
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4.1 Discussion of Results 
 
Two GC methods were developed and validated for the quantitation of three 
Tampoprint related leachables in two separate ophthalmic formulations with the 
ability to detect other volatiles that may turn up during the shelf life of each product. 
Chapter 2 sets out a method utilising direct injection GC while chapter 3 describes a 
method that employs HS-GC.  
Direct injection GC has until recently been the only method used within Allergan for 
detection of volatile leachables in their products. Recently though HS-GC was also 
introduced with some of the more complex sample matrices making use of the 
technique. However, as there is more knowledge and experience of the direct 
injection GC it is normal to develop new methods using the direct injection GC 
technique. Product Z has a rather simple sample matrix and therefore the direct 
injection GC was capable of producing good chromatography with a clear baseline. 
Product X on the other hand had a much more complex sample matrix which 
produced a lot of baseline interference and unsatisfactory resolution of the 
cyclohexanone, PGMMEA and PGMEEA. It was decided to test Product X using 
HS-GC which gave a much improved baseline and no interference of the 
aforementioned leachables. A polar Agilent DB-WAX column with a polyethylene 
glycol stationary phase was initially used with the HS-GC but poor peak shape was 
noted. The non-polar DB5 column (5% phenyl 95% dimethylpolysiloxane stationary 
phase) was trialled and produced much better chromatography with good sharp peaks 
for each leachable. 
 
Each method was validated in accordance with the current USP and ICH guidelines. 
These guidelines are intended to provide direction on how to accomplish validation 
of an analytical procedure and to demonstrate that it is fit for its intended purpose. 
The validation characteristics required for quantitative testing of impurities in these 
methods were accuracy, precision, specificity, detection limit, quantitation limit, 
linearity, range and robustness. System suitability parameters had to be established 
along with the stability of the analytical solutions to ensure that the validity of the 
analytical procedure is maintained whenever used.   
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One of the main differences between the two methods is how the standards are 
prepared. For direct injection the working standard is made up in a volumetric and 
transferred to GC vials for testing. Up to three injections can be taken from each vial 
meaning % RSD values tend to be quite low in comparison to the HS-GC method 
which incorporates a standards addition technique. This involves adding the standard 
to a specified aliquot of sample within a HS-GC vial. Only one injection can be made 
from each vial due to the loss of volatiles in the headspace after piercing the vial lid. 
This means that each working standard has to be individually prepared and thus 
creates higher % RSD results. For this reason the % RSD acceptance criteria for 
direct injection GC is 5% but for HS-GC it is 10%.  
 
Overall, the direct injection GC method gave better repeatability to that of the HS-
GC method. This is best illustrated when comparing the % RSDs from the system 
suitability results during robustness testing. Tables 2.12 and 2.13 show results for 
cyclohexanone and PGMMEA respectively for the direct injection GC method 
with % RSDs consistently below 1%. Tables 3.14 and 3.15 illustrate very 
inconsistent % RSDs for the HS-GC ranging from below 1% to nearly 7%. Due to 
the standard additions technique the HS-GC method is considerably more time 
consuming and also uses a lot more sample per analysis with 3 mL required for every 
standard preparation. Additionally, HS-GC vials are substantially more expensive 
than direct injection GC vials. For these reasons the direct injection GC method is 
therefore regarded as the preferred technique to test for volatiles within Allergan. 
However, the HS-GC method gave very good accuracy results as can be seen by the 
mean % recovery results in tables 3.19 and 3.20. Cyclohexanone and PGMMEA 
results were less than 100 ± 7% which is significantly better than those gained by the 
direct injection GC method. Tables 2.17 and 2.18 show that the mean % recovery 
results for cyclohexanone and PGMMEA were 100 ± 12% across the range of levels 
for the direct injection GC method. Furthermore, HS-GC gave a much better baseline 
as most of the sample matrix is not injected onto the column. Over time this also 
improves the longevity of the column and the GC system. It is therefore the 
preferable option for testing of volatiles within formulations that have a complex 
sample matrix.   
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4.2 Future Work 
 
Future work with HS-GC may involve investigating the option of multiple injections 
from HS-GC vials. The option is available on some HS-GC models and would mean 
less individual standards needing to be prepared hence improving repeatability, 
reducing preparation downtime and decreasing the amount of sample required. 
Another option is to increase the sensitivity of the HS-GC method. If peak areas can 
be enlarged repeatability will usually be improved and give more accurate and 
reliable results. This may be achieved by investigating the different operating 
parameters such as the vial oven temperature, time and different columns. The 
addition of a salt to the standard preparation could be investigated as this can help to 
decrease the solubility of organic volatiles in the sample matrix and promote their 
transfer into the headspace thus producing larger responses. 
Future work on direct injection GC may include exploring sample extractions for 
some of the more complex sample matrices. This could result in less sample matrix 
being injected onto the column and therefore give a better baseline. 
Due to limited time, standard stability was only tested for up to eight days for the 
direct injection GC method and seven days for the HS-GC method. It is thought that 
stability of standards for each method could also be increased as part of future work. 
 
  
 
 
 
 
 
 
